

## CURRICULUM VITAE

**STEFANO PALLANTI, M.D. PhD**

H-index: 58 (as of October 2021)

### EDUCATION

December 1983

Medical Doctorate Degree (M.D.) and European Medical License, 6-year course, final dissertation thesis "Life events and Depression"  
**University of Florence, School of Medicine, Florence, Italy**

November 1987

Residency In Psychiatry, 4-year course, final dissertation thesis "Life Events and Schizophrenia"  
**University of Florence, School of Medicine, Florence, Italy**

November 1988

Residency in NeuroPhysiopathology admitted to the second year.  
**University of Florence, School of Medicine, Florence, Italy**

June 1993

Ph.D in Neurophysiopathology, 4-year course, final dissertation thesis "Contingent Negative Variation in Normal Elderly Population "  
**University of Florence, School of Medicine, Florence, Italy**

May 2013

Certificate of Deep TMS Operation, completed by **Brainsway Inc., Israel**

May 2018

Certificate of completion of Electroconvulsive Therapy Training, completed by **Villa Baruzziana, Ospedale privato accreditato Neuropsichiatrco, Bologna, Italy**

### MEDICAL LICENSES

**Italian Licence to Practice, Registration at the Provincial Association of Doctor-Surgeons and Dentists in Florence, Italy:** Licenced on 30 November 1983, Registered on 23 January 1984, Licence number 7745

**General Medical Council (UK) Registration:** 18 June 2012, Registration n°7125393

**Schweizerische Eidgenossenschaft (Swiss Confederation) Registration:** 7 November 2012, Registration n° GNL7601000979667

**Medical Board of California, USA:** November 13, 2013 - November, 13 2014, Registration n°F5799, NPI n° 19322939038, DEA Registration number: FP4286628 (2113 Permit)

**Medical Board of California, USA:** March 29, 2018 - December 12, 2019, Registration n°SFP000035, NPI n° 19322939038, DEA Registration number: FP4286628 (2168 Permit)

## PROFESSIONAL APPOINTMENTS

### Present Employment

January 1989 - Present

Founder, Owner, CEO, Administrator, Strategic and Scientific Director, ***Istituto di Neuroscienze, Via A. Lamarmora 24, Firenze, Italy***, A private institution for research, diagnosis, rTMS and tDCS therapy in Psychiatry, Neurology and Clinical Psychology. Accredited by the University of Florence for Post-Graduate Internship.

January 2004 - Present

Founder, Director and Administrator, ***Clinical Neurosciences ONLUS, Via Dè Fossi 12, Firenze, Italy***, A non-profit organization that organizes scientific CME courses in collaboration with the University of Florence (Italy)

### Academic Appointments

2001 – 2020 Tenured Professor of Psychiatry ***University of Florence, School of Medicine, Florence, Italy***

2000 – 2010 Scientific Secretary and Coordinator, ***Tuscany School of Psychiatry*** (Three Tuscan Universities' Consortium: University of Florence, Pisa and Siena)

2004 Board Member and Coordinator, ***International Affairs Office of the University of Florence***

Since 2004 Member of Board of Directors, International Master in Affective Neuroscience, ***University of Maastricht, The Netherlands and University of Florence, Italy***

2004 – 2005 Visiting Associate Professor in Overseas Studies, ***Stanford Program in Florence, School of Humanities and Sciences, Stanford University***

2004 – 2005 Professor in Emergency Psychiatry, Emergency Medicine Post Doctorate Master course, ***Harvard School of Medicine, Massachusetts, U.S. and University of Florence, Florence, Italy***

2006 – 2007 Director and Organizer, Medical School Course of Psychiatry in English, ***University of Florence, Italy***

2007 – 2008 Director, Strategic Center of Excellence of Psychiatry, ***Icahn School of Medicine at Mount Sinai New York, USA***

Since 2008 Member of Board of Directors, Dottorato Toscano di Neuroscienze, ***University of Florence, School of Medicine, Florence, Italy***

2008 - 2010 Director of Master in Mindfulness (“Meditation and Mindfulness: Neurosciences and Clinical applications in Health Care”) ***University of Florence***

- Since 2010 Director of the Graduate Course on Health Education, **University of Florence, School of Medicine, Florence, Italy**
- Since 2010 Chair of Education and Director of the Residency Program of Psychiatry, **University of Florence, School of Medicine, Florence, Italy**
- Since 2012 Italian National Scientific Qualification as a full professor
- 2013 - 2014 Professor of Psychiatry and Behavioral Sciences, Early Diagnosis and Preventive Treatment Clinic, Psychosomatic Unit, Responsible for the Neuromodulation Program, **UC Davis, CA, USA**
- Since 2013 Visiting Professor, **Albert Einstein College of Medicine, Montefiore Medical Center New York, USA**
- 2013 Qualified as a Full Professor, University of Florence
- Since 2016 Visiting Professor, **Imperial College, London, UK**
- 2017 – 2019 Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology (Adult), **Stanford University, Stanford, CA, USA**
- Since 2018 Faculty, **Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale**
- Since 2019 Faculty, The European Network for Problematic Usage of the Internet, **Training School at Clare College, Cambridge University**
- Since 2019 Faculty, International Psychopharmacology Course, **Harvard University and Massachusetts General Hospital Psychiatry Academy**

#### Clinical Activities

- 1984 –1988 Chief Residency in Psychiatry
- 1988 –1990 Residency in Neurology
- 1990 –1993 Residency in Clinical Neurophysiology
- Since 1989 Clinical Director, **Istituto di Neuroscienze, Italy**
- 2000 – 2020 Dirigente Medico 1<sup>st</sup> level (Medical Director), **Psychiatric Clinic, Azienda Ospedaliero Universitaria Careggi (University of Florence Hospital), Department of Neuropharba**
- 2000 – 2020 Director of the OCD Spectrum Disorders programme, Psychiatric Clinic, **Azienda Ospedaliero Universitaria Careggi, University of Florence Hospital, Department of Neuropharba**
- 2009 - 2014 Director of Psychosomatic and Liaison psychiatry, Azienda Ospedaliera Universitaria Careggi, **University of Florence, Florence, Italy**

2013 - 2014 Clinical Practice, Sacramento EDAPT and EDAP programs (Early Diagnosis and Preventing Treatment of Psychosis Illness), Liaison Psychiatry Consultant, **UC Davis Medical Hospital, CA, USA**

2018 - 2019 Professor of Psychiatry and Behavioural Sciences, **Stanford University, CA, USA**

#### Professional Memberships and Services

1994 – Present International Advisory Board member, **American Psychiatric Association (APA) for DSM V and DSM 5.0 TR**

1999 - Present Member of the Steering Committee, **International OCD Consortium**

2002 - Present Member of Board of Directors, **International Master in Affective Neuroscience**, Universities of Maastricht and Florence

2004 - Present Board member, **International College of Obsessive-Compulsive Spectrum Disorders (ICOCS), UK**

2004 - Present Scientific Advisory Panel Member for Anxiety and Anxiolytics session, **European College of Neuropsychopharmacology (ECNP)**

2005 - Present Member of International Advisory Board, **American Psychiatric Association (APA) for DSM 5.0 (Chair D.J. Kupfer)**

2005 - 2007 Member of the OCD spectrum workgroup Impulse Control Disorders Taskforce and International Advisory Board, **American Psychiatric Association (APA) for DSM 5.0 (Chair D.J. Kupfer)**

2009 - Present Member of the Advisory Council, **icare4autism (International Center for Autism Research and Education), New York, USA**

2011 –2014 Member of the **European College of Neuropsychopharmacology Educational Committee**

2011 – Present Member of **the ECNP Obsessive Compulsive and Related Disorders Network**

2013 – Present Fellow, **European College of Neuropsychopharmacology**

2013 – Present Member of the **New York Psychiatric Society, NY, USA**

2013 - 2017 Member of the Board of Directors, **Clinical TMS Society, Greenwich, CT, USA**

2014 - Present **World Health Organization expert in Anxiety**

2014 - Present International Fellow, **American Psychiatric Association (APA)**

2015 - Present Member of the Board, (anxiety section) **World Psychiatric Association**

- 2015 - Present Member of the Board, (anxiety section) **World Psychiatric Association**
- 2016 - 2019 Executive Committee Member, **European College of Neuropsychopharmacology**
- 2017 - Present Member of the **PANDAS Physicians Network**
- 2018 – Present Board member, **European Research Area Networks NEURON (ERA-NET NEURON)**
- 2019 – Present Chair, Neuromodulation Network, **European College of Neuropsychopharmacology**
- 2020 International Expert, **German Association of Scientific Medical Associations on behalf of the German Society for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (DGKJPP)** for development of the interdisciplinary evidence- and consensus-based S3-Guideline for the diagnosis and treatment of obsessive-compulsive disorder in childhood and adolescence (interdisziplinäre evidenz- und konsensbasierte S3-Leitlinie für Diagnostik und Therapie von Zwangsstörungen im Kindes- und Jugendalter)
- 2020 – Present Member of the **International Neuroethics Society**
- 2020 – Present Board member, **The European Commission consensus initiative on depression and its treatment (EU PEARL)**
- 2021 – Present Member, WHO - World Health Organization funded **COVID-19 Clinical Research Coalition's Ethics Working Group, the Good Clinical Practice Alliance – Europe (GCPA)**

#### Service as a member of Grant Review Committee

- 2011 Member of Research Funding Evaluation Committee, **UK General Medical Research Council**
- Since 2011 Member of the Board of Research Funding Evaluation Committee SAMENTA, **Agence Nationale de la Recherche, Paris, France**
- 2013 Member of the Expert Review Board, The **ERA-NET scheme of the European Commission 'Network of European Funding for Neuroscience Research' (NEURON)** for its funding initiative "European Research Projects on Mental Disorders"
- Since 2018 Member of the Spark Evaluation Committee, **the Swiss National Science Foundation (SNSF)**
- 2020 Specialist Evaluating Committee Member, **National Research Foundation (NRF), South Africa**

#### Professional Honors and Awards

- October 2004 ECNP poster-travel award
- February 2005 Società Italiana di Psicopatologia (SOPSI) poster research award
- May 2007 CNS Spectrum 2007 Breakthrough Paper Award

## TEACHING

### Master Training Class in Neuromodulation, European College of Neuropsychopharmacology (ECNP)

Since 2020            Organizer and speaker for ECNP Network, Thematic Working Group  
University of Florence, Italy

- 1993 - 2019            Psychopathology Course (Course Director and Lecturer)
- 1993 – 2019            Psychopathology in the Residency Programme (Course Director and Lecturer)
- 2000 – 2019            Undergraduate Psychiatry Course (Course Director and Lecturer)
- 2001 – 2019            Medical Thesis Advisor
- 2006 - 2007            English language Medical School Course of Psychiatry (Director)
- 2007 – 2019            Suicide Prevention Course for Medical students, Nurse and Social Workers (Director)
- 2010 – 2019            Psychopharmacology Course (Course Director and Lecturer)
- 2012 – 2012            Master's Program in Mindfulness (Director)
- 2016 - 2017            Neurocircuitry Research Domain Criteria and Precision Psychiatry Course (Course Director and Lecturer)
- 2010 - Present        Post-Graduate Psychiatry Course (Course Director and Lecturer)

### Weekend Educative Course in Psychiatry, India

2017 – 2018            Elite faculty for enforcement program of neuropsychiatry in India

### University of Maastricht and University of Florence,

1995 - Present        International Master Degree in Affective Neuroscience (joint program) - course design, material development, lectures, and thesis advising

### Continuing Medical Education (CME) European Accreditation Council for CME

2009 - 2013            Managing Anxiety in Practice CME Course design, course material development (Slides, Booklet and CD-ROM) and lectures. Total of 6 courses held in Berlin (Germany), London (UK), Athens (Greece), Rome (Italy), Munich (Germany) and Paris (France)

## Florence Summer Course – Organizer, Scientific Director, Chair and Speaker

2004	7 - 14 Aug.	Anxiety and Impulsivity
2005	30 July - 1 Aug.	Neuroscience of Affective Disorder Spectrum
2006	14 -15 Sept.	Psychiatric Disorder and Day Hospital
2007	31 Ago. - 3 Sept.	Anxiety Disorders and Psychosis
2008	4 - 6 Sept.	Aspect of Contemporary Psychiatric Disorders
2009	5 - 7 Sept.	A Lesson on Great American Studies on Efficiency and Personalized Therapies in Psychiatry
2010	3 - 5 Sept.	Aspect of Contemporary Psychiatry
2011	9 - 11 Sept.	Toward and Individualized Therapy – Evolution of Psychiatry, from Disorder to “Research Domain”
2012	19 - 21 Oct.	Quality in Clinical Psychiatry
2013	11 - 12 Oct.	Clinical Staging and Pathophysiology of Brain Disease
2014	23 - 24 Oct.	Total Resources: Look after Brain Disorders and Take Care of Mental Suffering

## Coordinator, Interuniversity cooperation agreements

Since 2004 Board member of the International Affairs Office of the University of Florence, On-going International educational collaborative programmes between Univ. of Florence and:

Columbia University (USA) in 2010  
University of Balamand (Lebanon) in 2009  
Mount Sinai School of Medicine (USA) in 2004  
Stanford University (USA) in 2004

## SCHOLARSHIP

### Peer-Reviewed Original Research Publications

1. Faravelli C, Sacchetti E, Ambonetti A, Conte G, **Pallanti S**, Vita A. Recent life events and affective disorder revisited. *British Journal of Psychiatry*. 1986 Mar;148:288-95.
2. Faravelli C, Ambonetti A, **Pallanti S**, Pazzagli A. Depressive relapses and incomplete recovery from index episode. *American Journal of Psychiatry*. 1986 Jul;143(7):888-91.
3. Faravelli C, **Pallanti S**. Clomipramine by different routes of administration: short- and long-term efficacy and predictors of clinical outcome. *Psychopharmacol Bull*. 1987;23(3):459-63.
4. Faravelli C, **Pallanti S**, Frassine R, Albanesi G, Guerrini Degl'Innocenti B. Panic attacks with and without agoraphobia: a comparison. *Psychopathology*. 1988;21(1):51-6.
5. Faravelli C, **Pallanti S**, Strik WK. [Stress load and schizophrenic disorder]. *Nervenarzt*. 1988 Apr;59(4):237-9. German.

6. Faravelli C, **Pallanti S**. Recent life events and panic disorder. *American Journal of Psychiatry*. 1989 May;146(5):622-6.
7. Smeraldi E, Orsini A, Gasperini M, Sciuto G, Battaglia M, Cassano GB, Perugi G, Faravelli C, **Pallanti S**, Bressa G. Familial analysis of panic disorder and agoraphobia. *Journal of Affective Disorders*, 1989, vol.17, p.1-8. ISSN: 0165-0327.
8. Faravelli C, Guerrini Degl'Innocenti B, Aiazzi L, Incerpi G, **Pallanti S**. Epidemiology of mood disorders: a community survey in Florence. *Journal of Affective Disorders*. 1990 Oct;20(2):135-41.
9. Faravelli C, Panichi C, **Pallanti S**, Paterniti S, Grecu LM, Rivelli S. Perception of early parenting in panic and agoraphobia. *Acta Psychiatrica Scandinavica*. 1991 Jul;84(1):6-8.
10. Faravelli C, **Pallanti S**, Biondi F, Paterniti S, Scarpato MA. Onset of panic disorder. *American Journal of Psychiatry*. 1992 Jun;149(6):827-8.
11. **Pallanti S**, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. *Biological Psychiatry*. 1992 Jul 1;32(1):91-5.
12. Zaccara G, Gangemi PF, Muscas GC, Paganini M, **Pallanti S**, Parigi A, Messori A, Arnetoli G. Smooth-pursuit eye movements: alterations in Alzheimer's disease. *Journal of the Neurological Science*. 1992 Oct;112(1-2):81-9. Volume 112, Issues 1–2, 1992, Pages 81-89. ISSN 0022-510X. [https://doi.org/10.1016/0022-510X\(92\)90136-9](https://doi.org/10.1016/0022-510X(92)90136-9). (<https://www.sciencedirect.com/science/article/pii/0022510X92901369>)
13. M.Weissman, L.Bobins, J.Escobar, R.Bland, G.Canino, H.Wittchen, C.Faravelli, **S.Pallanti**, J.Lepine, P.Pariante, E.Karam, J.Wells, H.Hwu, G.Klerman, P.Lavori, W.Maier (1992). The changing rate of depression. *JAMA*, vol. 268, p. 3098-3105, ISSN: 0098-7484.
14. **Pallanti S.**, Pavia R.S. A demencia emu ma prospectiva psico (pato) lògica. [Dementia in a psycho(patho)logical perspective] *Jornal Brasileiro de Psiquiatria [Brazilian Journal of Psychiatry]* 41 (9), 447-50. Ott. 1992.
15. Faravelli C., **Pallanti S.**, Biondi F., Paterniti S., Scarpato M.A. Assessment of onset of panic disorder in relation to onset of agoraphobia-replay. *American Journal of Psychiatry* 150 (9), 1437-1437. 1993-09-01.
16. **Pallanti, S.** et al. Depth perception in schizophrenia. *Biological Psychiatry*, Volume 35, Issue 9, 637 – 638 Published in issue: May 01, 1994
17. Mortilla M, Amaducci L, Bruni A, Montesi MP, Trubnikov A, De Cataldo S, **Pallanti S**, Pazzagli A, Grecu L, Servi P, et al. Absence of APP713 mutation in Italian and Russian families with schizophrenia. *Neuroscience Letters* 1994 Jan 3;165(1-2):45-7.
18. Grassi E, Mortilla M, Amaducci L, **Pallanti S**, Pazzagli A, Galassi F, Guarnieri BM, Petrucci C, Bolino F, Ortenzi L, Nistico R, De Cataldo S, Rossi A, Sorbi S. No evidence of linkage between schizophrenia and D2 dopamine receptor gene locus in Italian pedigrees. *Neuroscience Letters* 1996 Mar 15;206(2-3):196-8.



19. **Pallanti S**, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L, Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive-compulsive disorder. *Biological Psychiatry*. 1996 Dec 1;40(11):1164-72.
20. **Pallanti S**, Koran LM. Two case report. *CNS Spectrums* 1996, vol.1, p.54-57, ISSN: 1092-8529.
21. Bersani G., Saito A. **Pallanti S**. Sasso E., Tosca P. Clinical variables and response to citalopram in Major Depression: an open multicentric study. *Rivista di Psichiatria* 32, 260-267, 1997.
22. **Pallanti S**. Personality Disorders: Myths and Neuroscience. *CNS Spectrums* 2, 53-63, 1997.
23. Koran LM, Sallee FR, **Pallanti S**. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. *American Journal of Psychiatry*. 1997 Mar;154(3):396-401.
24. **Pallanti S**, Quercioli L, Pazzagli A. Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. *American Journal of Psychiatry*. 1997 Jun;154(6):792-8.
25. Ramacciotti A, **Pallanti S**, Pazzagli A. A setting including psychotherapy and psychopharmacological treatment in a case of anorexia nervosa with obsessive compulsive disorder comorbidity. *Eating and Weight Disorders*. 1997 Dec;2(4):222-8.
26. Inzitari D, Pantoni L, Lamassa M, **Pallanti S**, Pracucci G, Marini P. Emotional arousal and phobia in transient global amnesia. *Archives of Neurology*. 1997 Jul;54(7):866-73.
27. **Pallanti S**, Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa. *Eating and Weight Disorders*. 1997 Dec;2(4):216-21.
28. **Pallanti S**, Quercioli L, Zaccara G, Ramacciotti AB, Arnetoli G. Eye movement abnormalities in anorexia nervosa. *Psychiatry Research*. 1998 Mar 20;78(1-2):59-70.
29. Koran LM, **Pallanti S**, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. *Eur Neuropsychopharmacol*. 1998 May;8(2):121-6.
30. Sallee FR, Koran LM, **Pallanti S**, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. *Biological Psychiatry*. 1998 Aug 1;44(3):220-7.
31. **Pallanti, s.**, Quercioli, L. Cognitive subjective disturbances of schizophrenia: Effect of atypical neuroleptics. *European Neuropsychopharmacology*, 1999
32. **Pallanti S.**, Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. *Journal of Psychophysiology* 13 (3), 203-203, 1999-01-01.

33. **Pallanti S**, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. *American Journal of Psychiatry*. 1999 May;156(5):796. 10327919.
34. **Pallanti S**, Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. *Psychiatry Research*. 1999 Jun 30;86(3):239-49.
35. **Pallanti S**, Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, Pini S, Cassano GB. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. *American Journal of Psychiatry*. 1999 Jul;156(7):1094-6.
36. **Pallanti S**, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. *European Psychiatry*. 1999 Apr;14(2):101-6.
37. **Pallanti S**, Quercioli L, Pazzagli A. Basic symptoms and P300 abnormalities in young schizophrenic patients. *Comprehensive Psychiatry*. 1999 Sep-Oct;40(5):363-71.
38. Pini S, Dell'Osso L, Mastrocinque C, Marcacci G, Papasogli A, Vignoli S, **Pallanti S**, Cassano G. Axis I comorbidity in bipolar disorder with psychotic features. *British Journal of Psychiatry* 1999.467-71.
39. **Pallanti S**, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. *Journal of Clinical Psychiatry*. 1999 Dec;60(12):819-23.
40. Di Russo F, Zaccara G, Ragazzoni A, **Pallanti S**. Abnormal visual event-related potentials in obsessive-compulsive disorder without panic disorder or depression comorbidity. *Journal of Psychiatric Research*. 2000 Jan-Feb;34(1):75-82.
41. **Pallanti S**, Quercioli L. Shame and psychopathology. *CNS Spectrums*. 2000 Aug;5(8):28-43.
42. **Pallanti S**, Quercioli L, Pazzagli A. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine. *CNS Spectrums*. 2000 Sep;5(9):29-43.
43. Rossi A, Arduini L, Stratta P, **Pallanti S**. Subjective experience and subjective response to neuroleptics in schizophrenia. *Comprehensive Psychiatry*. 2000 Nov-Dec;41(6):446-9.
44. Koran LM, **Pallanti S**, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. *European Neuropsychopharmacology*. 2001 Apr;11(2):169-72.
45. Hollander E., Bienstock C.A., Koran L.M., **Pallanti S.**, Marazzini D., Rasmussen S.A., Ravizza L., Benkelfat C., saxena S., Greenberg D.B., Sasson Y., Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. *Journal of Clinical Psychiatry* 63, 20-29, 12-2001.
46. **Pallanti S.**, Quercioli L. Alternative route of administration and titration of SRIs in anxious resistant patients:Two day-hospital experiences. *European Neuropsychopharmacology* 11, S312, 2001-12-31.

47. Ramacciotti A, Sorbello M, Pazzagli A, Vismara L, Mancone A, **Pallanti S**. Attachment processes in eating disorders. *Eat Weight Disord*. 2001 Sep;6(3):166-70.
48. Presta S, Marazziti D, Dell'Osso L, Pfanner C, **Pallanti S**, Cassano GB. Kleptomania: clinical features and comorbidity in an Italian sample. *Comprehensive Psychiatry*. 2002 Jan-Feb;43(1):7-12.
49. Hollander E, Bienstock CA, Koran LM, **Pallanti S**, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. *Journal of Clinical Psychiatry*. 2002;63 Suppl 6:20-9.
50. **Pallanti S**, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. *International Journal of Neuropsychopharmacology*. 2002 Jun;5(2):181-91.
51. **Pallanti S**, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. *Journal of Clinical Psychiatry*. 2002 Jul;63(7):559-64.
52. **Pallanti S**, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. *Journal of Clinical Psychiatry*. 2002 Sep;63(9):796-801.
53. **Pallanti S**, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. *Journal of Clinical Psychiatry*. 2002 Nov;63(11):1034-9.
54. Buchsbaum M.S., Hollander E., **Pallanti S**., Baldini-Rossi N. Brikman A.M., Platholi J., Sood E. Positron emission tomography. Imaging of risperidone augmentation in SRI-refractory patients. *Biological Psychiatry* 51 (8), 47S-47S, 2002-04-14.
55. **Pallanti S**., Rossi N.B., Friedberg J., Hollander E. Psychobiology of Impulse-Control Disorders Not Otherwise Specified (NOS). *Biological Psychiatry* 2003, 1315-1329.
56. Sood ED, **Pallanti S**, Hollander E. Diagnosis and treatment of pathologic gambling. *Current Psychiatry Reports*. 2003 May;5(1):9-15.
57. Hollander E, Baldini Rossi N, Sood E, **Pallanti S**. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. *International Journal of Neuropsychopharmacology*. 2003 Dec;6(4):397-401.
58. **Pallanti S**, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. *American Journal of Psychiatry*. 2004 Jan;161(1):53-8.
59. **Pallanti S**, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. *Journal of Clinical Psychiatry*. 2004 Oct;65(10):1394-9.

- 60.** Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. *Journal of Clinical Psychiatry*. 2004;65 Suppl 14:6-10.
- 61.** Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? *American Journal of Psychiatry*. 2005 Jan;162(1):137-45.
- 62.** Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological treatments of pathological gambling. *Journal of Gambling Studies*. 2005 Spring;21(1):99-110.
- 63.** Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, Licalzi EM, Tang C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. *Biological Psychiatry*. 2005 Apr 1;57(7):733-42.
- 64.** Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. *Dermatologic Clinics*. 2005 Oct;23(4):601-8.
- 65.** Pallanti S, Lotti T, Urpe M. Psychoneuroimmunodermatology of atopic dermatitis: from empiric data to the evolutionary hypothesis. *Dermatologic Clinics*. 2005 Oct;23(4):695-701.
- 66.** Hollander E, Pallanti S, Baldini Rossi N, Sood E, Baker BR, Buchsbaum MS. Imaging monetary reward in pathological gamblers. *World Journal of Biological Psychiatry*. 2005;6(2):113-20.
- 67.** Pallanti S, Lassi S, La Malfa G, Campigli M, Di Rubbo R, Paolini G, Cesarali V. Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. *Clinical Practice & Epidemiology in Mental Health*. 2005 Nov 15; 1:24.
- 68.** Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability, and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). *Journal of Gambling Studies*. 2005 Winter;21(4):431-43.
- 69.** Rossi A, Rucci P, Mauri M, Maina G, Pieraccini F, Pallanti S, Endicott J; (For the EQUIP group). Reliability and validity of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. *Quality of Life Research*. 2005 Dec;14(10):2323-8.
- 70.** Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2006 May;30(3):400-12.
- 71.** Pallanti, S. (2006). From Impulse-Control Disorders Toward Behavioral Addictions. *CNS Spectrums*. 11. 921-922. 10.1017/S1092852900015108.
- 72.** Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. *Neuropsychobiology*. 2006;53(3):157-68.

- 73. Pallanti S**, Bernardi S, Quercioli L, DeCaria C, Hollander E. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. *CNS Spectrums*. 2006 Dec;11(12):956-64.
- 74. Pallanti S**, Bernardi S, Quercioli L. The Shorter PROMIS Questionnaire and the Internet Addiction Scale in the assessment of multiple addictions in a high-school population: prevalence and related disability. *CNS Spectrums*. 2006;11(12):966-74.
- 75. Pallanti S**, Quercioli L. Resistant social anxiety disorder response to Escitalopram. *Clinical Practice & Epidemiology in Mental Health*. 2006;13; 2:35.
- 76.** Hollander E, Kim S, Khanna S, **Pallanti S**. Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. *CNS Spectrums*. 2007 Feb;12(2 Suppl 3):5-13.
- 77.** Fineberg NA, Pampaloni I, **Pallanti S**, Ipser J, Stein DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. *International Clinical Psychopharmacology* 2007;22(6):313-22.
- 78. Pallanti S**, Sandner C. Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. *International Journal of Psychiatry in Clinical Practice*. 2007; 11(3): 233-238.
- 79. Pallanti S**. Transcultural observations of obsessive-compulsive disorder. *American Journal of Psychiatry*. 2008 Feb;165(2):169-70.
- 80. Pallanti S**, Masetti S, Bernardi S, Innocenti A, Markella M, Hollander E. Obsessive compulsive disorder comorbidity in DBA. *Clinical Practice & Epidemiology in Mental Health*. 2008 Mar 10; 4:6.
- 81.** La Malfa G, Lassi S, Bertelli M, **Pallanti S**, Albertini G. Detecting attention-deficit/hyperactivity disorder (ADHD) in adults with intellectual disability the use of Conners' Adult ADHD Rating Scales (CAARS). *Research in Developmental Disabilities*. 2008 Mar-Apr;29(2):158-64.
- 82. Pallanti S**. Brain plasticity and brain stimulation in neuropsychiatry: toward individualized medicine. *CNS Spectrums*. 2008 Apr;13(4):287-92.
- 83.** Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W, Goodman CR, LiCalzi EM, Newmark R, **Pallanti S**. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral, and cingulated metabolism. *Neuropsychobiology*. 2008;58(1):37-47.
- 84. Pallanti S**, Hollander E. Obsessive-compulsive disorder spectrum as a scientific "metaphor". *CNS Spectrums*. 2008 Sep;13(9 Suppl 14):6-15.
- 85.** Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., **Pallanti S.**, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in the treatment of obsessive-compulsive disorder. *Biological Psychiatry* 63 (7), 170S-170S, 2008-04-01.

- 86. Pallanti S, Bernardi S.** Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety: a critical review. *International Clinical Psychopharmacology* 2009 Jul;24(4):163-73.
- 87. Faravelli C, Lo Sauro C, Castellini G, Ricca V, Pallanti S.** Prevalence, and correlates of mental disorders in a school-survey sample. *Clinical Practice & Epidemiology in Mental Health* 2009 Nov 24; 5:1-8.
- 88. Pallanti S, Castellini G, Chamberlain SR, Quercioli L, Zaccara G, Fineberg NA.** Cognitive event-related potentials differentiate schizophrenia with obsessive-compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC symptoms. *Psychiatry Research*. 2009 Nov 30;170(1):52-60.
- 89. Potenza MN, Koran LM, Pallanti S.** The relationship between impulse-control disorders and obsessive-compulsive disorder: a current understanding and future research directions. *Psychiatry Research*. 2009 Nov 30;170(1):22-31.
- 90. Bernardi S, Pallanti S.** Internet addiction: a descriptive clinical study focusing on comorbidities and dissociative symptoms. *Comprehensive Psychiatry*. 2009 Nov-Dec;50(6):510-6.
- 91. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E.** Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. *CNS Drugs*. 2009 Dec;23(12):1047-55.
- 92. Lisanby SH, Pallanti S, Schlaepfer TE.** FDA considers classification of ECT. *CNS Spectrums*. 2009 Dec;14(12):668-70.
- 93. Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L.** Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? *Neuroscience*. 2010;5;167(2):323-8.
- 94. Pallanti S, Bernardi S, Raglione LM, Marini P, Ammannati F, Sorbi S, Ramat S.** Complex repetitive behavior: punting after bilateral subthalamic nucleus stimulation in Parkinson's disease. *Parkinsonism and Related Disorder*. 2010 Jul;16(6):376-80.
- 95. Cecchelli C, Grassi G, Pallanti S.** Aripiprazole Improves Depressive Symptoms, and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression. *Case Reports in Medicine*. 2010; 2010:836214.
- 96. Schlaepfer TE, Lisanby SH, Pallanti S.** Separating hope from hype: some ethical implications of the development of deep brain stimulation in psychiatric research and treatment. *CNS Spectrums*. 2010 May;15(5):285-7.
- 97. Pallanti S., Schlaepfer T.E., Lisanby S.H.** The Clinical Future of Repetitive Transcranial Magnetic Stimulation and Depression: Separating Hope From Hype. *CNS Spectrums* 15 (9), 554-557, 2010.
- 98. Pallanti S, Haznedar MM, Hollander E, Licalzi EM, Bernardi S, Newmark R, Buchsbaum MS.** Basal Ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study. *Neuropsychobiology*. 2010;62(2):132-8.

- 99. Pallanti S.** Problematic Internet use: is it more compulsory than rewarding or mood driven? *World Psychiatry*. 2010 Jun;9(2):96-7.
- 100. Bernardi S, Cortese S, Solanto M, Hollander E, Pallanti S.** Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. *World Journal of Biological Psychiatry*. 2010 Jun;11(4):656-66.
- 101. Pallanti S, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E.** Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine. *Journal of Psychopharmacology*. 2010 Jun;24(6):847-53.
- 102. Bernardi S, Pallanti S.** Successful duloxetine treatment of a binge eating disorder: a case report. *Journal of Psychopharmacology*. 2010 Aug;24(8):1269-72.
- 103. Pallanti S, Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A, Zaccara G, Cincotta M.** Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation investigation. *Journal of Neurology*. 2010 Aug;257(8):1362-8.
- 104. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Bruguá M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P.** European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. *BMC Psychiatry*. 2010;3; 10:67.
- 105. Pallanti S.** Augmentation strategies in resistant obsessive-compulsive disorders (OCD), *International Journal of Psychiatry in Clinical Practice* 14, 15-16, 2010-11-01.
- 106. Pallanti S, Bernardi S, Allen A, Hollander E.** Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. *Journal of Psychopharmacology*. 2010 Dec;24(12):1802-9.
- 107. Pallanti S.** Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. *CNS Spectrums*. 2010 Mar;15(3):154-6.
- 108. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E.** Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. *Journal of Clinical Psychiatry*. 2011 May;72(5):716-21. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript
- 109. Di Rollo A, Pallanti S.** Phantom limb pain: low frequency repetitive transcranial magnetic stimulation in unaffected hemisphere. *Case Reports in Medicine*. 2011; 2011:130751.
- 110. Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C.** The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Psychological Medicine*. 2011 Aug 16:1-13. \*Provided study ideas and concept, participated in the drafting and revision of the manuscript, and provided mentorship to first author

- 111. Pallanti S**, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications. *Front Psychiatry*. 2011; 2:70.
- 112.** Valenti R, Pescini F, Antonini S, Castellini G, Poggesi A, Bianchi S, Inzitari D, **Pallanti S**, Pantoni L. Major depression and bipolar disorders in CADASIL: a study using the DSM-IV semi-structured interview. *Acta Neurologica Scandinavica*. 2011 Dec;124(6):390-5. \*Participated extensively in conception and trial design, acquisition, analysis and interpretation of data, participated in drafting, reviewing and critical revision of the manuscript.
- 113.** Baldwin DS, Allgulander C, Bandelow B, Ferre F, **Pallanti S**. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. *World Journal of Biological Psychiatry*. 2012; 13(7):510-6.
- 114. Pallanti, S.**, Grassi, G. and Cantisani, A. (2012). Approaches to Treatment Resistance. In *Obsessive-Compulsive Disorder*, J. Zohar (Ed.) <https://doi.org/10.1002/9781119941125.ch5>
- 115.** Moretti S, Arunachalam M, Colucci R, **Pallanti S**, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. *Journal of the European Academy of Dermatology and Venereology*. 2012; 26(7):861-7. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript
- 116. Pallanti S**, Cantisani A, Grassi G, Antonini S, Cecchelli C, Burian J, Cauli G, Quercioli L. rTMS age-dependent response in treatment resistant depressed subjects: a mini-review, *CNS Spectrums* (2012), 17, 24-30.
- 117. S. Pallanti**, A. Di Rollo, S. Antonini, E. Hollander and L.Quercioli Low Frequency rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant Depression: Cognitive Improvement is Independent from Clinical Response, *Neuropsychobiology* 2012 Jun; 65(4):227-35.
- 118.** Moretti S., Arunachalam M., Colucci R., **Pallanti S.**, Kline JA., Berti S., Lotti F., Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. *Journal of the European Academy of Dermatology and Venereology* 2012; 26 (7), 861-867. \*Participated extensively in conception, drafting, reviewing and critical revision of the manuscript.
- 119. Pallanti S**, Salerno L. Pharmacological treatment and management of attention deficit hyperactivity disorder (ADHD) in adults. *Minerva Psichiatrica* 2013 Dec; 54(4);297-315. ISSN: 1827-1731
- 120. Pallanti. S.** The Placebo Effect in Clinical Practice. *American Journal of Psychiatry* 2013 170:8, 931-932
- 121.** Bandinelli F, Prignano F, Bonciani D, **Pallanti S**, Lotti T, Salaffi F, Bartoli F, Candelieri A, Giovannini L, Maddali Bongi S, Matucci-Cerinic M. Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). *Clinical and*



Experimental Rheumatology. 2012;31(2):318-9. \*Participated extensively in conception, drafting, reviewing and critical revision of the manuscript

**122.** Pallanti, S., Grassi, G. and Cantisani, A. (2012). Approaches to Treatment Resistance. In Obsessive-Compulsive Disorder, J. Zohar (Ed.) <https://doi.org/10.1002/9781119941125.ch5>

**123.** Baldwin DS, **Pallanti S**, Zwanzger P. Developing a European Research Network to Address Unmet Needs in Anxiety Disorders. Neuroscience and Biobehavioral Reviews. 2013; 37(10 Pt 1):2312-7. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

**124.** Valenti R, Salvadori E, Pescini F, Poggesi A, Castellini G, Antonini S, Bianchi S, Inzitari D, **Pallanti S**, Pantoni L., Facial Affect Recognition in CADASIL Patients., Archives of Clinical Neuropsychology 2013;28(1):65-71. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

**125.** Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, **Pallanti S**, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World Journal of Biological Psychiatry. 2013;(2): 121-128. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

**126.** **Pallanti S**, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia. Current Psychiatry Reports. 2013;15(5):354.

**127.** Dell'Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N, Stein DJ, **Pallanti S**, Nicolini H, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder, a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). European Neuropsychopharmacology. 2013 Aug; 23(8):865-71. \*Participated extensively in conception and trial design, acquisition and analysis of data, participated in drafting, reviewing and critical revision of the manuscript

**128.** **Pallanti S**, Grassi G, Tofani T, Spitoni S. Pharmacological Treatments for Behavioral Addictions: From Behavioral Dimensions to the Research Domain Criteria Based Target. Current Psychopharmacology, 2013; 2(3):183-189.

**129.** Marras A, **Pallanti S**. Transcranial magnetic stimulation for the treatment of pharmacoresistant nondelusional auditory verbal hallucinations in dementia. Case Reports in Psychiatry. 2013; 2013:930304.

**130.** **Pallanti S**, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectrums. 2014; 19(1):50-61.

**131.** Carelli R, **Pallanti S**. Streptococcal infections of skin and PANDAS. Dermatologic Therapy. 2014 Jan; 27(1):28-30.

- 132.** Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, **Pallanti S**. Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. *CNS Spectrums*. 2014; 9(4):340-6.
- 133.** Van Ameringen S, Simpson W, Patterson B, Dell'Osso B, Fineberg N, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, **Pallanti S**, Stein DJ, Zohar, J. Pharmacological treatment strategies in obsessive-compulsive disorder: A cross-sectional view in nine international OCD centers. *Journal of Psychopharmacology* 2014; 28(6):596-602. \*Participated extensively in conception and trial design, authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript
- 134.** Di Rubbo R., Sogaro E., **Pallanti, S**. Communicative evolutive psychotherapy adapted for the psychodynamic group setting in the treatment of pathological interpersonal dynamics of identity. *Dynamische Psychiatrie*. 2013; 46(3): 204-233.
- 135.** **Pallanti S**, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive disorders. *Expert Opin Emerg Drugs*, 2014 Mar; 19(1):66-77.
- 136.** **Pallanti S**, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in resistant mixed states: An exploratory study. *J Affect Disord*. 2014; 157:66-71.
- 137.** **Pallanti S**, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. *Eur Neuropsychopharmacol*. 2014; 24(3):375-380.
- 138.** **Pallanti S**, Grassi G, Ramella Cravaro V, Goodman W.K. From Psychopathology to neurocircuits: what we can learn from DBS? The case of obsessive-compulsive disorder. *J. Psychopathol*. 2014; 20:27-32.
- 139.** Aguglia E, Biggio G, Signorelli MS, Mencacci C; **Steering Committee on behalf of the STIMA-D Investigators**. Italian Study on Depressive Disorders (STudio Italiano MAattia Depressiva, or STIMA-D): a nationwide snapshot of the status of treatment for major depression. *Pharmacopsychiatry*. 2014 May;47(3), 105-10. \*Member: **Pallanti S**. \*Acquisition of data
- 140.** **Pallanti S**, Tofani T, Zanardelli M, Di Cesare mannelli L, Ghelardini C. BDNF and ARTEMIN are increased in drug-naive non-depressed GAD patients: preliminary data. *International Journal of Psychiatry in Clinical Practice*. 2014; 18(4):255-60.
- 141.** Lochner C, Fineberg NA, Zohar J, Van Ameringen M, Juven\_Wetzler A, Altamura AC, Cuzen NL, Hollander E, Denys D, Nicolini H, Dell'Osso B, **Pallanti S**, Stein DJ, Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorder (ICOCS). *Comprehensive Psychiatry*. 2014;55(7):1513-9. \*Participated extensively in conception and trial design, drafting, reviewing and critical revision of the manuscript
- 142.** **Pallanti S**, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder comorbidity. *Expert Opin Pharmacother*. 2014;15(17):2543-52.

- 143.** Mucci A, Rucci P, Rocca P, Bucci P, Gibertoni D, Merlotti E, Galderisi S, Maj M; **Italian Network for Research on Psychoses**. The Specific Level of Functioning Scale: construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. *Schizophrenia Research*. 2014; 159(1):144-50. \*Member: **Pallanti S**. \*Acquisition of data
- 144.** Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell'Osso L, De Ronchi D, Di Emidio G, Di Giannantonio M, Fagiolini a, Marchesi C, Monteleone P, Oldani L, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A, Zeppegno P, Maj M; Italian Network for Research on Psychoses. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World Psychiatry*. 2014; 13(3):275-87. \*Member: **Pallanti S**. \*Acquisition of data
- 145.** Cantisani, A., Grassi, G., Pagano, L., Comanducci, A., Lanzo, G., Amantini, a., Grippo, a., Salerno, L., **Pallanti, S**. Neurophysiological alterations in adults with attention deficit/hyperactivity disorder: an event-related potential study. *European Neuropsychopharmacology* 24:S714-S715 · October 2014. DOI: 10.1016/S0924-977X(14)71151-4
- 146.** Grassi G, Godini L, Grippo A, Piccagliani D, **Pallanti S**. Enhancing Cognitive-behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. *Brain Stimulation*. 2015; 8(1):160-1.
- 147.** **Pallanti S**, Salerno L. Raising attention to attention deficit hyperactivity disorder in schizophrenia. *World Journal of Psychiatry*. 2015;5(1):47-55.
- 148.** Grassi, G., **Pallanti, S**. Citalopram Pulse-Loading for Treatment-Resistant Obsessive-Compulsive Disorder: Preliminary Data from an Open-Label Trial. *European Neuropsychopharmacology*, Volume 26, Issue 5, 2016, Pages 898-899, ISSN 0924-977X, <https://doi.org/10.1016/j.euroneuro.2015.06.034>.
- 149.** Dell'Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, Marazziti D, Hollander E, Fineberg N, Stein DJ, **Pallanti S**, Van Ameringen M, Lochner C, Hranov N, Karamustafalioglu O, Hranov L, Zohar J, Denys d, Altamura AC, Menchon JM. Cigarette smoking in patients with obsessive compulsive disorder: a report from International College of Obsessive Compulsive Spectrum Disorder (ICOCS). *CNS Spectrums*. 2015; 20(5):469-73. \*Participated extensively in conception, participated in drafting, reviewing and critical revision of the manuscript
- 150.** Uzunova G, **Pallanti S**, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorder: Implications for interventions and therapeutics. *World Journal of Biological Psychiatry*. 2015; 15:1-13. \*Authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript
- 151.** **Pallanti, S.**, Grassi G, Marras A, Hollander E. Can we modulate obsessive-compulsive networks with neuromodulation? *J Psychopatol*, 21:262-265.
- 152.** **Pallanti, S.**, Marras A, Grassi G. Outcomes with neuromodulation in obsessive-compulsive disorder. *Psych Annals*, 45(6):316-320.

- 153. Pallanti, S.,** Marras, A. Transcranial Magnetic Stimulation Treatment for Motor Symptoms in Parkinson's Disease: A Review of Two Decades of Studies. *Journal of Alzheimer's Disease & Parkinsonism*. 05. 10.4172/2161-0460.1000191.
- 154. Pallanti, S.,** Marras, A. Transcranial Magnetic Stimulation in Alzheimer's Disease: A Review of Investigational and Therapeutic Findings. *J Alzheimers Dis Parkinsonism* 5:187. doi:10.4172/2161-0460.1000187
- 155.** Grassi, G., Molesti E., Lori S., Pallanti S., Cheli E., Marras A. "OR-38: neuromodulation of decision-making networks with alphaEEG-guided repetitive transcranial magnetic stimulation: preliminary results from a pilot study." *Journal of Behavioral Addictions*, vol. 5, no. S1, 2016, p. 17+.
- 156.** Grant J E, Fineberg N, Van Ameringen A, Cath D, Visser H, Carmi L, **Pallanti S**, Hollander E, Van Balkom A J, New treatment models for compulsive disorders. *European Neuropsychopharmacology* 2016; 26(5):877-84. \*Participated extensively in conception, acquisition of data, authorship of sections of the manuscript
- 157.** Grassi G, **Pallanti S**, Righi L, Figeo M, Mantione M, Denys D, Piccagliani D, Rossi A, Stratta P. Think twice: Impulsivity and decision making in obsessive-compulsive disorder. *Journal of Behavioral Addiction* 2015;4(4):263-72. \*Provided study ideas, participated in the drafting, reviewing and revision of the manuscript, and provided mentorship to first author
- 158. Pallanti S,** Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review, and pilot open-label trial. *Journal of Psychopharmacology*. 2016; 30(6):568-78.
- 159.** Menchon JM, Van Ameringen M, Dell'Osso B, Denys D, Figeo M, Grant JE, Hollander E, Marazziti D, Nicolini H, **Pallanti S**, Ruck R, Stein DJ, Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov , Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R, Pasquini M, Perez Rivera R, Poyurovsky M, Real E, do Rosario MC, Sreni N, Swinson RP, Vulink N, Zphar J, Fineberg N. Standards of care for obsessive-compulsive disorders centres. *International Journal of Psychiatry in Clinical Practice*. 2016;20(3):204-8. \*Participated extensively in conception and trial design, acquisition of data and in drafting
- 160.** Marras A, Fineberg N, **Pallanti S**. Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11. *CNS Spectrums*. 2016;21(4):324-33.
- 161.** Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Grunblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, **Pallanti S**, Pini S, Strohle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. *World Journal of Biological Psychiatry*. 2016; 15:1-53. \*Participated extensively in conception and trial design, acquisition, authorship of sections of the manuscript
- 162.** Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation. *J*

Psychiatr Res. 2016 Dec;83:240-248. doi: 10.1016/j.jpsychires.2016.09.012. Epub 2016 Sep 14. PMID: 27665536.

**163.** Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, **Pallanti S**, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hranov L, Figeo M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *International Journal of Psychiatry in Clinical Practice*. 2016; 19:1-8. \*Participated extensively in conception and trial design, acquisition of data and in drafting

**164. Pallanti S.** ICD and DSM: Neuroplasticity and Staging are still missing. *CNS Spectrums*. 2016 Aug;21(4):276-8.

**165.** Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Blasi G, Comparelli A, Di Giannantonio M, Goracci A, Marchesi C, Monteleone P, Montemagni C, Pinna F, Roncone R, Siracusano A, Stratta P, Torti MC, Vita A, Zeppegno P, Chieffi M, Maj M; **Italian Network for Research on Psychoses**. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. *Schizophr Res* 2016; 175(1-3):154-60. \*Member: **Pallanti S**. \*Participated extensively in conception and trial design, acquisition, analysis of data, reviewing and critical revision of the manuscript

**166.** Rocca P, Galderisi S, Rossi A, Bertolino A, Rucci P, Gibertoni D, Montemagni C, Sigauo M, Mucci A, Bucci P, Acciavatti T, Aguglia E, Amore M, Bellomo A, De Ronchi D, Dell'Osso L, Di Fabio F, Girardi P, Goracci A, Marchesi C, Monteleone P, Niolu C, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Zeppegno P, Maj M; **Italian Network for Research on Psychoses**. Social cognition in people with schizophrenia: a cluster-analytic approach. *Psychol Med* 2016 Oct;46(13):2717-2729 \*Member: **Pallanti S**. \*Participated extensively in conception and trial design, acquisition, participated in drafting, reviewing and critical revision of the manuscript

**167.** Menchón JM, van Ameringen M, Dell'Osso B, Denys D, Figeo M, Grant JE, Hollander E, Marazziti D, Nicolini H, **Pallanti S**, Ruck C, Shavitt R, Stein DJ, Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov G, Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R, Pasquini M, Pérez Rivera R, Poyurovsky M, Real E, do Rosário MC, Soreni N, Swinson RP, Vulink N, Zohar J, Fineberg N. Standards of care for obsessive-compulsive disorder centres. *Int J Psychiatry Clin Pract*. 2016 Sep;20(3):204-8. \*Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript

**168.** Giordano F, Cavallo M, Spacca B, **Pallanti S**, Tomaiuolo F, Pieraccini F, Fagiolini A, Grandoni M, Melani F, Zicca A, Sestini S, Genitori L. Deep Brain Stimulation of the Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive Behaviour. *Stereotact Funct Neurosurg*. 2016 Nov 1;94(6):371-378. \*Participated extensively in conception and trial design, acquisition of data and in drafting

**169.** Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, **Pallanti S**, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hranov L, Figeo M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates

in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *Int J Psychiatry Clin Pract.* 2016 Nov;20(4):210-7. \*Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript

**170.** Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, **Pallanti S.** Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation. *J Psychiatr Res.* 2016 Dec; 83:240-248.

**171.** Chiariello F, Spitoni S, Hollander E, **Pallanti S.** An expert opinion on PANDAS/PANS: highlights and controversies. *International Journal of Psychiatry in Clinical Practice* 2017; 1-8 Published online: 13 Feb 2017

**172.** Salerno L, Makris N, **Pallanti S.** Raadult ADHD: a key feature. *Journal of Psychopathology* 2016; 22:135-140.

**173. Pallanti S.** Biological Markers for Anxiety Disorders, OCD and PTSD – A Consensus Statement – Part II: Neurochemistry, Neurophysiology and Neurocognition. *The World Journal of Biological Psychiatry World J Biol Psychiatry.* 2017 Apr;18(3):162-214.

**174.** Dell'Osso B, Benatti B, Arici C, Palazzo C, Altamura AC, Hollander E, Fineberg N, Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, **Pallanti S**, van Ameringen M, Lochner C, Karamustafalioglu O, Hranov L, Figeo M, Drummond L, Rodriguez CI, Grant J, Denys D, Menchon JM, Zohar J. Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *CNS Spectr.* 2017 Mar 16:1-8.

**175.** Dell'Osso B, Marazziti D, Albert U, **Pallanti S**, Gambini G, Tundo A, Zanaboni C, Servello D, Rizzo R, Scalone L, Benatti B, Altamura C, Porta M. Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. *Int J Psychiatry Clin Pract.* 2017 Jun;21(2):156-159.

**176.** Salerno L, Burian I, **Pallanti S.** A new generation rating scale for depression: Reliability and Validity of the Italian version of Symptoms of Depression Questionnaire (SDQ), an RDoC-oriented depression comprehensive assessment. *Journal of Psychopathology*, 2017 23:1-12.

**177.** Grassi, G., Pacini, S., Cecchelli C., **Pallanti, S.** Enhancing inhibition processes during cognitive-behavioral therapy in obsessive-compulsive disorder with repetitive transcranial magnetic stimulation. S1009. *European Neuropsychopharmacology*, 2017

**178.** Grassi, G., & Pallanti, S. (2017). Common Neural Networks Between OCD and Behavioural Addictions: Is LCD a Behavioural Addiction? *European Psychiatry*, 41(S1), S21-S22. Doi:10.1016/j.eurpsy.2017.01.120

**179.** Lusicic A, Schruers KR, **Pallanti S**, Castle DJ. Transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: current perspectives. *Neuropsychiatr Dis Treat.* 2018 Jun 29;14:1721-1736. doi: 10.2147/NDT.S121140. PMID: 29988759; PMCID: PMC6029675.

- 180.** Micheli L., Spitoni S, Di Cesare Mannelli L., Billa A.R., **Pallanti S.** Bacopa Monnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. 01 April 2020 <http://10.1002/ptr.6684>
- 181.** Grassi G, Figeo M, Ooms P, Righi L, Nakamae T, **Pallanti S**, Schuurman R, Denys D. Impulsivity and decision-making in obsessive-compulsive disorder after effective deep brain stimulation or treatment as usual. *CNS Spectr.* 2018 Jun 4:1-7
- 182.** Burchi E, **Pallanti S.** Antibiotics for PANDAS? Limited Evidence: Review and Putative Mechanisms of Action. *Prim Care Companion CNS Disord.* 2018 May 3;20(3).
- 183.** Burchi E, **Pallanti S.** Diagnostic Issues in Early-Onset Obsessive-Compulsive Disorder and Their Treatment Implications. *Curr Neuropharmacol.* 2018 Apr 26.
- 184.** Fineberg NA, Chamberlain SR, Menchon J, Demetrovics D, Grünblatt E, **Pallanti S**, Carmi L, Billieux J, King D, Dellosso B, Van Ameringen M, Hall N, Potenza M, Hollander E, Zohar J and the COST Action EU-PUI Network. Manifesto for a European Research Network into Problematic Usage of the Internet. 2018, in submission.
- 185.** Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van Ameringen M, Corazza O, **Pallanti S**; COST Action Network, Chamberlain SR. Version 2. Manifesto for a European research network into Problematic Usage of the Internet. *Eur Neuropsychopharmacol.* 2018 Nov;28(11):1232-1246. Doi: [10.1016/j.euroneuro.2018.08.004](https://doi.org/10.1016/j.euroneuro.2018.08.004). Epub 2018 Oct 10. PMID: 30509450
- 186.** Burchi E, Hollander E, **Pallanti S.** From Treatment Response to Recovery: A Realistic Goal in OCD. *Int J Neuropsychopharmacol.* 2018 Nov 1;21 (11):1007-1013. doi: [10.1093/ijnp/pyy079](https://doi.org/10.1093/ijnp/pyy079). PMID:30184141
- 187.** Grassi G, **Pallanti S.** Expert Opinion *Pharmacother.* 2018 Oct;19(14):1541-1550. Doi:[10.1080/14656566.2018.1528230](https://doi.org/10.1080/14656566.2018.1528230). Epub 2018 Oct 15. PMID:3021070
- 188.** Sali L, Ventura L, Grazzini G, Borgheresi A, Delsanto S, Falchini M, Mallardi B, Mantellini P, Milani S, **Pallanti S**, Zappa M, Mascalchi M. Patients' experience of screening CT colonography with reduced and full bowel preparation in a randomised trial. *Eur Radiol.* 2018 Nov 6. doi: [10.1007/s00330-018-5808-1](https://doi.org/10.1007/s00330-018-5808-1). [Epub ahead of print] PMID:30402705
- 189.** Scarpino, M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu Cesarina, Bastianelli M, Occupati B, Lanzi C, **Pallanti S**, Amantini A, Mannaioni G, Grippo A. Efficacy of high-frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS) of the left premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake (the Magne Tox study): A study protocol for a randomized placebo-controlled pilot trial. *Neurophysiologie Clinique*, 10 2018
- 190.** Grassi, G., Pallanti, S. Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults, *Expert Opinion on Pharmacotherapy*, 19:14, 1541-1550, DOI: [10.1080/14656566.2018.1528230](https://doi.org/10.1080/14656566.2018.1528230) 2018
- 191.** J.J.S. Kooija, D. Bijlengaa, L. Salerno, R. Jaeschkea, I. Bittera, J. Balázsa, J. Thomea, G. Doma, S. Kaspera, C. Nunes Filipea, S. Stesa, P. Mohra, S. Leppämäkia, M.

Casas Bruguéa, J. Bobesa, J.M. Mccarthy, V. Richartea, A. Kjems Philipsena, A. Pehlivanidis,b , A. Niemela, B. Styr, B. Semerci, B. Bolea-Alamanac, D. Edvinsson, D. Baeyens, D. Wynchank, E. Sobanski, A. Philipsen, F. McNicholas, H. Caci, I. Mihailescu, I. Manor,b , I. Dobrescu,b , J. Krause,b , J. Fayyad, J.A. Ramos-Quiroga, K. Foeken, F. Rad, M. Adamou, M. Ohlmeier, M. Fitzgerald, M. Gill, M. Lensing, N. Motavalli Mukaddes, P. Brudkiewicz, P. Gustafsson, P. Tani, P. Oswald, P.J. Carpentier, P. De Rossi, R. Delorme, S. Markovsk, Simosk, **S. Pallanti**, S. Young, S. Bejerot, T. Lehtonen, J. Kustow, U. Müller-Sedgwick, T. Hirvikoski, V. Pironti, Y. Ginsberg, Z. Félégeházy, M.P. Garcia-Portilla, P. Asherson., Updated European Consensus Statement on diagnosis and treatment of adult ADHD; *European Psychiatry* 56 (2019) 14–34 accepted 3 Nov 2018

**192.** Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van Ameringen M, Corazza O, **Pallanti S**; COST Action Network, Chamberlain SR., Manifesto for a European research network into Problematic Usage of the Internet. *Eur Neuropsychopharmacol.* 2018 Nov;28(11):1232-1246. doi: 10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID:30509450

**193.** Scarpino M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu C, Bastianelli M, Occupati B, Lanzi C, **Pallanti S**, Amantini A, Mannaioni G, Grippo A., Efficacy of high-frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS) of the left premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake (the MagneTox Study): A study protocol for a randomized placebo-controlled pilot trial. *Neurophysiol Clin.* 2019 Feb;49(1):1-9. doi: 10.1016/j.neucli.2018.10.002. Epub 2018 Oct 26. PMID:30712533

**194.** Grassi, G., Pacini, S., Cecchelli, C., **Pallanti, S.** Enhancing Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder with Transcranial Magnetic Stimulation: A proof of concept. *European Neuropsychopharmacology*, Volume 28, Issue 6, 2018, Pages 766-767, ISSN 0924-977X, <https://doi.org/10.1016/j.euroneuro.2017.10.008>.

**195.** Grassi G., Makris N., **Pallanti S.** Olfaction in gambling disorder: an exploratory study. *Journal of Behavioral Addictions.* ICBA2018 / April 23–25, 2018 / Cologne, Germany. Vol 7., Supplement 1. [www.academai.com](http://www.academai.com)

**196.** Fineberg NA, Dell'Osso B, Albert U, Maina G, Geller D, Carmi L, Sireau N, Walitza S, Grassi G, **Pallanti S**, Hollander E, Brakoulias V, Menchon JM, Marazziti D, Ioannidis K, Apergis-Schoute A, Stein DJ, Cath DC, Veltman DJ, Van Ameringen M, Fontenelle LF, Shavitt RG, Costa D, Diniz JB, Zohar J., Early intervention for obsessive compulsive disorder: An expert consensus statement. *Eur Neuropsychopharmacol.* 2019 Feb 14. pii: S0924-977X(19)30159-2. doi: 10.1016/j.euroneuro.2019.02.002. [Epub ahead of print] PMID:30773387

**197.** Hollander E., Van Ameringen M., Nicolini H., Zohar J., **Pallanti S.**, Nezgoverova V., Fineberg N. E. 01.01 Pharmacological Treatment of resistant OCD. *European Neuropsychopharmacology*, 2019 vol29, S32, Elsevier

**198.** Marras A., Gavazzi G., Grassi G., Rathi Y., Mascalchi M., Makris N., Camprodon J.A., **Pallanti S.** Abstract59: Modulating Inhibitory Control Networks in Gambling Disorder with Theta Burst Stimulation. *Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation.* Elsevier. 2019 Mar 1., Vol 12, issue 2, e21.



- 199.** Salerno L., Ramat S., Solari G., Grassi G., **Pallanti S.** Parkinson's Disease with Impulse Control Disorders: Higher Prevalence (Frequency) of Symptoms of Attention Deficit Hyperactivity Disorder International Journal of Clinical Psychiatry 2019, 7(1): 1-7 DOI: 10.5923/j.ijcp.20190701.01
- 200.** Burchi E., Makris N., Lee MR., **Pallanti S.**, Hollander E. Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation. 2019, Front. Behav. Neurosci. | doi: 10.3389/fnbeh.2019.00070
- 201.** Sacchetti, E. **Pallanti, S.** Bowden-Jones, H. (2019). Archives of Behavioral Addictions: A new journal for a new era. *Archives of Behavioral Addictions*, 1(1). doi:10.30435/ABA.01.2019.01
- 202.** Grassi G., Makris N., **Pallanti S.** Addicted to compulsion: assessing three core dimensions of addiction across obsessive-compulsive disorder and gambling disorder. *CNS Spectr.* 2019 May 20:1-10. doi: 10.1017/S1092852919000993. [Epub ahead of print] PMID:31106718
- 203.** Dell'Osso B., Vismara M., Benatti B., Cirnigliaro G., Grancini B., Fineberg N., Van Ameringen M., Hollander E., Stein D., Menchon JM., Rodriguez C., Nicolini H., Lanzagorta N., **Pallanti S.**, Grassi G., Lochner C., Marazziti D., Hranov G., Karamustafalioglu O., Hranov L., Zohar J. Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *CNS Spectrums*. doi 10.1017/S1092852919001068 Published online: 27 May 2019
- 204.** Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, **Pallanti S**, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. *Eur Neuropsychopharmacol.* 2019 Jun 26. pii: S0924-977X (19)30266-4. doi: 10.1016/j.euroneuro.2019.06.008. [Epub ahead of print] Review. PMID:31255396
- 205.** Davis JM. Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E., Kasper, S., **Pallanti S.**, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. *Eur Neuropsychopharmacol.* 2019 Sep;29(9):1061-1062. doi: 10.1016/j.euroneuro.2019.07.001. Epub 2019 Jul 29. No abstract available. PMID: 31371104
- 206.** Kooij JJS, Bijenga D, Salerno L, Jaeschke R, Bitter I, Balazs J, Thome J, Dom G, Kasper S, Nunes FC, Stes S, Mohr P, Leppamaki S, Casas M, Bobes J, Mccarthy JM, Richarte V, Kjemis PA, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea-Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipsen A, McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Saito T, Krause J, Fayyad J, Ramos-Quiroga JA, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill M, Lensing M, Motavalli Mukaddes N, Brudkeiwicz P, Gustafsson P, Tani P, Oswald P, Carpentier PJ, De Rossi P, Delorme R, Markovska Simoska S, **Pallanti S**, Young S, Bejerot S, Lehtonen T, Kustow J, Muller-Sedgwick U, Hirvikoski T, Pironti V, Ginsberg Y, Felegyhazy Z, Garcia-Portilla MP, Asherson P. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. *Eur Psychiatry* 2019 Feb; 56:14-34. doi: 10.1016/j.eurpsy.2018.11.001. Epub 2018 Nov 16.

- 207.** Pasquini M., Brakoulias V., **Pallanti S.** Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders. *Front Psychiatry*. 2020 Feb 25; 11:93. doi: 10.3389/fpsy.2020.00093. ECollection 2020.
- 208.** Fineberg N.A., Van Ameringen M., Drummond L., Hollander E., Stein D.J., Geller D., Walitza S., **Pallanti S.**, Pellegrini L., Zohar J., Rodriguez C.I., Menchon J.M., Morgado P., Mpavaenda D., Fontenelle L.F., Feusner J.D., Grassi G., Lochner C., Veltman D.J., Sireau N., Carmi L., Adam D., Nicolini H., Dell'Osso B. cu obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive. Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. Doi.org/10.1016/j.comppsy.2020.152174. 0010-440X/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)
- 209.** Fontenelle LF, Oldenhof E, Eduarda Moreira-de-Oliveira M, Abramowitz JS, Antony MM, Cath D, Carter A, Dougherty D, Ferrão YA, Figuee M, Harrison BJ, Hoexter M, Soo Kwon J, Küelz A, Lazaro L, Lochner C, Marazziti D, Mataix-Cols D, McKay D, Miguel EC, Morein-Zamir S, Moritz S, Nestadt G, O'Connor K, **Pallanti S**, Purdon C, Rauch S, Richter P, Rotge JY, Shavitt RG, Soriano-Mas C, Starcevic V, Stein DJ, Steketee G, Storch EA, Taylor S, van den Heuvel OA, Veale D, Woods DW, Verdejo-Garcia A, Yücel M. A Transdiagnostic perspective of constructs underlying obsessive-compulsive and related disorders: An international Delphi consensus study. *Aust N Z J Psychiatry*. 2020 May 4:4867420912327. doi: 10.1177/0004867420912327. [Epub ahead of print] PMID: 32364439
- 210.** Benatti B, Ferrari S, Grancini B, Girone N, Briguglio M, Marazziti D, Mucci F, Dell'Osso L, Gambini O, Demartini B, Tundo A, Necci R, De Berardis D, Galentino R, De Michele S, Albert U, Rigardetto S, Maina G, Grassi G, **Pallanti S**, Amerio A, Amore M, Priori A, Servello D, Viganò C, Bosi M, Colombo A, Porta M, Dell'Osso B. Suicidal ideation and suicidal attempts in patients with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder: results of a multicenter Italian study. *CNS Spectr*. 2020 May 6:1-8. doi: 10.1017/S1092852920001157. [Epub ahead of print] PMID: 32372727
- 211.** Galderisi S, Rucci P, Mucci A, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M, Bellomo A, Bozzatello P, Bucci P, Carpiniello B, Collantoni E, Cuomo A, Dell'Osso L, Di Fabio F, di Giannantonio M, Gibertoni D, Giordano GM, Marchesi C, Monteleone P, Oldani L, Pompili M, Roncone R, Rossi R, Siracusano A, Vita A, Zeppegno P, Maj M; **Italian Network for Research on Psychoses\***. The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. \*Member: **Pallanti, S.** *World Psychiatry*. 2020 Feb;19(1):81-91. doi: 10.1002/wps.20700.PMID: 31922687
- 212.** Fontenelle, L. F., Oldenhof, E., Eduarda Moreira-de-Oliveira, M., Abramowitz, J. S., Antony, M. M., Cath, D. C., Carter, A., Dougherty, D., Ferrão, Y. A., Figuee, M., Harrison, B. J., Hoexter, M., Soo Kwon, J., Küelz, A., Lazaro, L., Lochner, C., Marazziti, D., Mataix-Cols, D., McKay, D., Miguel, E.C., Morein-Zamir, S., Moritz, S., Nestadt, G., O'Connor, K., **Pallanti, S.**, Purdon, C., Rauch, S., Richte, P., Rotge, J.Y., Shavitt, R.G., Soriano-Mas, C., Stein, D.J., Steketee, G., Sorch, E.A., Taylor, S., Van den Heuvel, O.A., Veale, D., Woods, D.W., Verdejo-Garcia, A., Yucel, M. The International OCRDs Neuroscience

Consensus Group (2020). A transdiagnostic perspective of constructs underlying obsessive-compulsive and related disorders: An international Delphi consensus study. *Australian & New Zealand Journal of Psychiatry*, 54(7), 719-731. <https://doi.org/10.1177/0004867420912327>

- 213.** Fineberg, Naomi A.<sup>a,,b,,c;</sup> Hollander, Eric<sup>d;</sup> **Pallanti, Stefano**<sup>e,,f;</sup> Walitza, Susanne<sup>g,,h,,i;</sup> Grünblatt, Edna<sup>g,,h,,i;</sup> Dell'Osso, Bernardo Maria<sup>i,,k,,l,,m;</sup> Albert, Umberto<sup>n;</sup> Geller, Daniel A.<sup>o;</sup> Brakoulias, Vlasios<sup>p,,q;</sup> Janardhan Reddy, Y.C.<sup>r;</sup> Arumugham, Shyam Sundar<sup>r;</sup> Shavitt, Roseli G.<sup>s;</sup> Drummond, Lynne<sup>t;</sup> Grancini, Benedetta<sup>b,,j;</sup> De Carlo, Vera<sup>b,,j;</sup> Cinosi, Eduardo<sup>a,,b;</sup> Chamberlain, Samuel R.<sup>u,,v;</sup> Ioannidis, Konstantinos<sup>u,,v;</sup> Rodriguez, Carolyn I.<sup>k,,w;</sup> Garg, Kabir<sup>b;</sup> Castle, David<sup>x;</sup> Van Ameringen, Michael<sup>y,,z;</sup> Stein, Dan J.<sup>aa;</sup> Carmi, Lior<sup>bb,,cc;</sup> Zohar, Joseph<sup>bb,,dd;</sup> Menchon, Jose M.<sup>ee</sup> Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders, *International Clinical Psychopharmacology*: July 2020 - Volume 35 - Issue 4 - p 173-193 doi: 10.1097/YIC.0000000000000314
- 214.** **Pallanti S.** Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology. *Compr.Psychiatry*.2020;100:152184. Doi: 10.1016/j.comppsy.2020.152184
- 215.** **Pallanti S,** Grassi E, Makris N, Gasic GP, Hollander E. Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae [published online ahead of print, 2020 Aug 15]. *J Psychiatr Res*. 2020;130:215-217. doi: 10.1016/j.jpsychires.2020.08.008
- 216.** Netto, V.D.M., Flores, C., **Pallanti, S.** Pharmacological Treatment for Comorbid Bipolar Disorder and Obsessive-Compulsive Disorder in Adults, *Journal of Psychiatric Practice*: September 2020 - Volume 26 - Issue 5 - p 383-393. doi: 10.1097/PRA.0000000000000499
- 217.** Gaur S, **Pallanti S.** Treatment Outcomes in an Adult Attention Deficit Hyperactivity Disorder Clinic with a Focus on Executive Functioning and Sluggish Cognitive Tempo. *Cureus* 12(8): e9814. doi: 10.7759/cureus.9814
- 218.** **Pallanti, S.,** Porta, F., Salerno, L., Adult attention deficit hyperactivity disorder in patients with fibromyalgia syndrome: Assessment and disabilities, *Journal of Psychiatric Research*, 2020, ISSN 0022-3956, <https://doi.org/10.1016/j.jpsychires.2020.10.027>. (<http://www.sciencedirect.com/science/article/pii/S002239562031030X>)
- 219.** Castro-Calvo, J., King, D. L., Stein, D. J., Brand, M., Carmi, L., Chamberlain, S. R., Demetrovics, Z., Fineberg, N. A., Rumpf, H.-J., Yücel, M., Achab, S., Ambekar, A., Bahar, N., Blaszczynski, A., Bowden-Jones, H., Carbonell, X., Chan, E. M. L., Ko, C.-H., de Timary, P., Dufour, M., Grall-Bronnec, M., Lee, H. K., Higuchi, S., Jimenez-Murcia, S., Király, O., Kuss, D. J., Long, J., Müller, A., **Pallanti, S.**, Potenza, M. N., Rahimi-Movaghar, A., Saunders, J. B., Schimmenti, A., Lee, S.-Y., Siste, K., Spritzer, D. T., Starcevic, V., Weinstein, A. M., Wölfling, K., and Billieux, J. (2021) Expert appraisal of criteria for assessing gaming disorder: An international Delphi study. *Addiction*, <https://doi.org/10.1111/add.15411>.
- 220.** Uzunova, G., Pallanti, S., Hollander, E. (2021) Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and

in the post-COVID-19 recovery phase, *International Journal of Psychiatry in Clinical Practice*, DOI: [10.1080/13651501.2021.1887264](https://doi.org/10.1080/13651501.2021.1887264)

- 221.** Castle D, Beilharz F, Phillips KA, Brakoulias V, Drummond LM, Hollander E, Ioannidis K, Pallanti S, Chamberlain SR, Rossell SL, Veale D, Wilhelm S, Van Ameringen M, Dell'Osso B, Menchon JM, Fineberg NA. Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. *Int Clin Psychopharmacol*. 2021 Mar 1;36(2):61-75. doi: 10.1097/YIC.0000000000000342. PMID: 33230025; PMCID: PMC7846290.
- 222.** **Pallanti S.** Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the other Non-Invasive Brain Stimulation (NIBS) in the era of brain connectivity, *European Neuropsychopharmacology*, Elsevier, Editorial.  
<https://doi.org/10.1016/j.euroneuro.2021.03.004>
- 223.** Salerno L., **Pallanti S.** COVID-19 Related Distress in Gambling Disorder. *Frontiers in Psychiatry*. VOLUME12. 2021. pp156.  
<https://www.frontiersin.org/article/10.3389/fpsy.2021.620661>.  
[DOI10.3389/fpsy.2021.620661](https://doi.org/10.3389/fpsy.2021.620661). ISSN1664-0640
- 224.** Grassi, G., Figeo, M., Stratta, P., Rossi, A., & Pallanti, S. (2016). Response to Cognitive impulsivity and the behavioral addiction model of obsessive-compulsive disorder: Abramovitch and McKay (2016), *Journal of Behavioral Addictions J Behav Addict*, 5(3), 398-400. Retrieved Apr 9, 2021, from <https://akjournals.com/view/journals/2006/5/3/article-p398.xml>
- 225.** Pallanti S, Salerno L. ADHD: the dark side of Eating Disorders. *Evidence-based Psychiatric Care* 2016;2:24-31, [http://www.evidence-based-psychiatric-care.org/wp-content/uploads/2016/07/05\\_pallanti.pdf](http://www.evidence-based-psychiatric-care.org/wp-content/uploads/2016/07/05_pallanti.pdf). ISSN: 2421-4469
- 226.** Pallanti, S., Marras, A., Dickson, S. L., Adan, R. A. H., Vieta, E., Dell'Osso, B., Arango, C., Fusar-Poli, P., Soriano-Mas, C., Carmi, L., Meyer-Lindenberg, A., Zohar, J. Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty, *European Neuropsychopharmacology*, Volume 52, 2021, Pages 72-83, ISSN 0924-977X, <https://doi.org/10.1016/j.euroneuro.2021.07.002>.  
(<https://www.sciencedirect.com/science/article/pii/S0924977X21002728>)
- 227.** Castro-Calvo J, King DL, Stein DJ, Brand M, Carmi L, Chamberlain SR, Demetrovics Z, Fineberg NA, Rumpf HJ, Yücel M, Achab S, Ambekar A, Bahar N, Blaszczyński A, Bowden-Jones H, Carbonell X, Chan EML, Ko CH, de Timary P, Dufour M, Grall-Bronnec M, Lee HK, Higuchi S, Jimenez-Murcia S, Király O, Kuss DJ, Long J, Müller A, **Pallanti S**, Potenza MN, Rahimi-Movaghar A, Saunders JB, Schimmenti A, Lee SY, Siste K, Spritzer DT, Starcevic V, Weinstein AM, Wölfling K, Billieux J. Expert appraisal of criteria for assessing gaming disorder: an international Delphi study. *Addiction*. 2021 Jan 15. doi: 10.1111/add.15411. Epub ahead of print. PMID: 33449441.

1. **Pallanti S.** The anxiety-psychosis spectrum. *CNS Spectrums*. 2000 Sep;5(9):22.
2. **Pallanti S.**, Transcultural Observations of Obsessive-Compulsive disorder, *American Journal of Psychiatry*, 165:2, February 2008
3. **Pallanti S.**, Problematic Internet Use: is it more compulsory than rewarding or mood driven? *World Psychiatry*.2010 Jun;9(2):96-7.
4. **Pallanti S.** Transcultural observations of obsessive-compulsive disorder. *American Journal of Psychiatry*. 2008 Feb;165(2):169-70.
5. **Pallanti S.** Problematic Internet use: is it more compulsory than rewarding or mood driven? *World Psychiatry*. 2010 Jun;9(2):96-7.
6. Grassi G, Godini L, Grippo A, Piccagliani D, **Pallanti S.** Enhancing Cognitive-behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. *Brain Stimulation*.2014.10.18.
7. Pasquini M., Brakoulias V., **Pallanti S.** Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders. *Front. Psychiatry* 11:93. doi: 10.3389/fpsy.2020.00093
8. **Pallanti S.** Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the other Non-Invasive Brain Stimulation (NIBS) in the era of brain connectivity, *European Neuropsychopharmacology*, Elsevier, Editorial. <https://doi.org/10.1016/j.euroneuro.2021.03.004>

#### Peer-Reviewed Abstracts

1. **Pallanti S.**, Zuccarini S., Rivelli A., Quercioli L., Pazzagli A. Depth perception in schizophrenia. *Biological Psychiatry* 35 (9), 637-638. 1994-05-01.
2. Koran L., Sallee F., **Pallanti S.**, Paiva R., Quercioli L. Intravenous pulse loading of clomipramine in obsessive-compulsive disorder. *Psychopharmacology Bulletin* 32 (3), 466-466. Nov. 1996.
3. Di Russo F., Zaccara G., **Pallanti S.**, Gangemi P., Lori S., Ragazzoni A. Visual event-related potentials in obsessive-compulsive disorders. *Electroencephalography and Clinical Neurophysiology* 103 (1), 211-211, Jul 1997.
4. **Pallanti S.**, Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. *Journal of Psychophysiology* 13 (3), 203-203, 1999-01-01.
5. Russo F., Zaccara G., Ragazzoni A. **Pallanti S.** Abnormal visual ERPs in obsessive-compulsive deficits in young schizophrenic patients. *Journal of Psychophysiology* 13 (3), 207-207, 1999-01-01.
6. **Pallanti S.**, Quercioli L. Reboxetine in bulimia nervosa: An open study. *Biological Psychiatry* 49 (8), 105S-106S. 2001-04-05.
7. Quercioli L., Bruscoli M., **Pallanti S.** P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. *European Neuropsychopharmacology* 14, S186, 2004-10-31.
8. **Pallanti S.**, Quercioli L. Reboxetine in bulimia nervosa: An open study. *Biological Psychiatry* 49 (8), 105S-106S. 2001-04-05.
9. Quercioli L., Bruscoli M., **Pallanti S.** P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. *European Neuropsychopharmacology* 14, S186, 2004-10-31.
10. **Pallanti S.**, Baker B.R., Chaplin W., Kim S., De Caria C., Bernardi S., Hollander E., Noradrenergic function in pathological gambling. *Biological Psychiatry*. 2006;59 (8), 32S-32S.

11. Bernardi S., Ramat S., Raglione L., Marini P., Sorbi S., Ammannati F., **Pallanti S.** Punding after bilateral subthalamic nucleus stimulation in Parkinson's disease. *European Psychiatry* 23, S350-S351.
12. Cincotta M., Borgheresi A., Pampaloni I., Giovannelli F., Bernardi S., Cantisani A., Zaccara G., **Pallanti S.** P27-7 Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation study. *Clinical Neurophysiology* 121, s265, 2010-20-31.

#### Peer-Reviewed Letters and Commentary

1. Marazziti D, **Pallanti S.** Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. *American Journal of Psychiatry*. 1999 Nov;156(11):1834-5.
2. **Pallanti S.** "Dr. Pallanti Replies." *American Journal of Psychiatry*, 2000 157(5):840-a-840.
3. Hollander E, **Pallanti S.** "5-HT1D Function and Repetitive Behaviors." *American Journal of Psychiatry*, 2001 158(6):972-a-973.
4. **Pallanti S.**, Quercioli L, Hollander E. "Dr. Pallanti and Colleague Reply." *American Journal of Psychiatry*, 2005 162(2): 400-a-401.
5. Faravelli C., **Pallanti S.**, Biondi F., Paterniti S., Scarpato M.A. Dr. Faravelli and Associates Reply. *American Journal of Psychiatry* 150 (9), 1437-1437. 1993-09-01.
6. Grassi G, Figeo M, Stratta P, Rossi A, **Pallanti S.** Response to Cognitive impulsivity and the behavioral addiction model of obsessive-compulsive disorder: Abramovitch and McKay (2016). *J Behav Addict*. 2016 Sep;5(3):398-400.
7. Koran LM, Faravelli C, **Pallanti S.** Intravenous clomipramine for obsessive-compulsive disorder. *Journal of Clinical Psychopharmacology* 1994 Jun;14(3):216-8
8. Marazziti D, **Pallanti S.** Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. *American Journal of Psychiatry*. 1999 Nov;156(11):1834-5.
9. Hollander E, **Pallanti S.** 5-HT(1D) function and repetitive behaviors. *American Journal of Psychiatry*. 2001 Jun;158(6):972-3.
10. **Pallanti S.**, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. *American Journal of Psychiatry*. 1999 May;156(5):796.

#### Peer-Reviewed Book Reviews

1. **Pallanti S.** Obsessive-Compulsive Disorder: Theory, Research, and Treatment. *American Journal of Psychiatry* 1999; 156:1108a-1109.
2. **Pallanti S.** Panic Disorder: Clinical Diagnosis, Management and Mechanism. *American Journal of Psychiatry* 158(7), 1176-a-1177. 2001-07-01. Book Review
3. **Pallanti S.** Panic Disorder: Clinical Diagnosis, Management and Mechanism. *American Journal of Psychiatry* 158(7), 1176-a-1177. 2001-07-01.
4. **Pallanti S.** Review of perfectionism: theory, research and treatment. *American Journal of Psychiatry* 2004, vol.161 (8).

#### Other Publications

1. **Pallanti S.** Vincenzo Chiarugi, 1759-1820. *American Journal of Psychiatry*. 1996 Jul;153(7):944.
2. **Pallanti S.** Images in Psychiatry. Ugo Cerletti. 1877-1963 Essay. *American Journal of Psychiatry* 156.630-630, 1999.

3. **Pallanti S.** Obsessive-Compulsive Disorder: Theory, Research, and Treatment. *American Journal of Psychiatry* 1999; 156:1108a-1109
4. **Pallanti S.**, Quercioli L. SSRIs in the treatment of premenstrual dysphoric disorder. Nefazodone: An open trial. *European Neuropsychopharmacology* 10(S3), 127-128, 2000-09-30
5. **Pallanti S.** Pathological Gambling, A clinical guide to treatment, American Psychiatric Publishing, 2004, Introduction
6. **Pallanti S.** From impulse-control disorders toward behavioral addictions. *CNS Spectrums*. 2006;11(12):921-922.
7. **Pallanti S.** Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. *CNS Spectrums*. 2010 Mar;15(3):154-6.
8. **Pallanti S.**, Book Review: Comprehensive care of schizophrenia: a textbook of clinical management, 2nd edition. *American Journal of Psychiatry*. 2013 Jan 1;170(1):125-126.
9. **Pallanti S.**, Strategies for Treatment Resistant OCD, *Psychiatric Times*. 2014.

### Book Chapters

1. **Pallanti S.**, Rossi L., De Palma G., Checchi M., Muscas C., Faravelli C. Electroencephalogram mapping in sodium lactate-induced panic attacks: Preliminary results. **Imaging of the Brain in Psychiatry and Related Fields**, pp 281-284, Edited by K. Maurer, Springer, 1993
2. Current and Experimental Therapeutics of Obsessive Compulsive Disorders, pp 1647 – 1664, *Neuropsychopharmacology: The Fifth Generation of Progress, An Official Publication of the American College of Neuropsychopharmacology*, Edited by K.L. Davis, D. Charney, J.T. Coyle and C. Nemeroff, Lippincott/Williams and Wilkins, 2002
3. Psychobiology of Impulse Control Disorders Not Otherwise Specified (NOS), pp 1315 – 1329, **Biological Psychiatry**, Edited by H. D’Haenen, J.A. den Boer, P. Willner, John Wiley & Sons Ltd., 2002
4. Sood E, **Pallanti S**, Hollander E. Serotonin reuptake inhibitors in the treatment of pathological gambling. *Essential Psychopharmacology*, pp 157-169, Edited by R. Murray, Cambridge University Press, 2002
5. Pharmacological Treatments, pp 189 – 200, **Pathological Gambling: A Clinical Guide to Treatment**, Edited by J. E. Grant, M. Potenza, American Psychiatric Publishing, 2004
6. Pathological Gambling, pp 251 – 289, **Clinical Manual of Impulse Control Disorders**, Edited by E. Hollander, D. Stein, American Psychiatric Publishing, 2006
7. Approaches to treatment resistance, pp. 99-117, **Obsessive Compulsive Disorder: Current Science and Clinical Practice**, Edited by J. Zohar, John Wiley & Sons, LTD, 2012
8. Positron Emission Tomography. Edited by Miscaglia, S. pp.177 – 188. Chapter 7, Santoro D., **Pallanti S.** Pathological Gambling: PET Studies. December 18th 2013 DOI: 10.5772/57537 ISBN: 978-953-51-1213-6 eBook (PDF) ISBN: 978-

953-51-7188-1 Copyright year: 2013

9. Pharmacological treatment of Autism Spectrum Disorders, pp. 151 – 166, **Autism Spectrum Disorders- Phenotypes, Mechanisms and treatment**, Edited by M. Leboyer, P. Chaste, Karger Medical and Scientific Publishers, 2015
10. New Technologies in Autism: Non-invasive Brain Stimulation, **Autism Spectrum Disorders**, Enticott PG, **Pallanti S**, Ring R, Pascual-Leone A, Hollander E., Edited by E. Hollander, D. Fein, P.J. Hagerman. Karger Medical and Scientific Publishers, 2017 [in press]
11. Incompleteness and Harm Avoidance in OCD, pp. Obsessive-Compulsive Disorder – Phenomenology, Pathophysiology and Treatment, **Pallanti S**, Barns J, Pittenger C, Eisen, J., Edited by Pittenger C. Oxford University Press, 2017
12. Handbook of Psychiatry and Behavioral Health, pp. 73 – 81, Malingering Fictitious Disorder: The Assessment of Competence and (Capacity) and Forensic Aspects., Organs and Living Donors, and Transplantation; The so-called “Biological Testament”. Carocci Editori Roma, March 2020
13. Consultant to: Long version of the interdisciplinary evidence- and consensusbased (S3) guideline “Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults” AWMF Registration No. 028-045. Published at AWMF online. Association of Analytical Child and Adolescent Psychotherapists in Germany (Vereinigung Analytischer Kinder- u. Jugendlichen-Psychotherapeuten in Deutschland e. V., VAKJP)
14. Salerno L, Gaur S, Grassi G, Pallanti S. Neuromodulation in Attention-Deficit/Hyperactivity Disorder: Toward a Precision Psychiatry Approach Chapter in Bernardo Dell'Osso and Giorgio Di Lorenzo (Eds): Non Invasive Brain Stimulation in Psychiatry and Clinical Neurosciences, 978-3-030-43355-0, 479307\_1\_En, (9)

## Books

1. **Pallanti S.**, Vivere con le Voci, Vivere nel Silenzio, (Live with Voices, Live in Silence, La nuova Italia Scientifica (1996)
2. Fossi G., **Pallanti S.**, Manuale di Psichiatria (Manual of Psychiatry), Casa Editrice Ambrosiana, Milano (1993)
3. **Pallanti S.**, Koran L. M., Treatment of OCD Resistant Patients, Airon (2003)
4. **Pallanti S.**, Bruscoli M., Le Emergenze Psichiatriche in Medicina, (Psychiatric Emergency in Medicine) Lippincott /Williams and Wilkins, (2006) sold exclusively by Innova Pharma SpA, Milano
5. Fossi G., **Pallanti S.**, Psichiatria Elementare (Elementary Psychiatry), La Nuova Italia Scientifica S.p.A. Roma. First edition 1993, 6th edition 2008
6. **Pallanti, S.** and Lauriello, J., Clinical Manual for Schizophrenia, Edited by B. Hales, American Psychiatric Publishing. (2010)
7. **Pallanti, S.** and Formosa, A., Stress? No grazie, siamo resiliente, (Stress? No Thank you, We are resilient) Trevisini Editore. (2011)
8. **Pallanti, S.**, Oltre la Schizophrenia (Beyond Schizophrenia) Edra LSWR (2015)
9. Fossi, G., **Pallanti, S.**, Psichiatria Elementare (Elementary Psychiatry), Carocci Editori, First edition 1999, Reprint 2015



10. **Pallanti, S.**, Psichiatria Elementare – Oltre il DSM-5 (Elementary Psychiatry – Beyond DSM -5), Carocci Editori, (2017)
11. **Pallanti S** Salerno L. The Burden of Adult ADHD in Comorbid Psychiatric and Neurological Disorders; Springer International Publishing 2020
12. **Pallanti S** Psichiatria e Salute Comportamentale Carocci Editori 2020
13. Ossessioni e compulsioni. Le ritualità propiziatorie tra neuroscienze, demonologia e psicoterapia. Talmelli R., Pallanti S., Bormolini G., Nardone G. Giunti editori 2021

#### Editor for an Italian Edition Book

1. BAARS-IV (Barkley Adult ADHD Rating Scale-IV), Russell A. Barkley, Hogrefe (2017), **Pallanti S.**, Salerno L.
2. The American Psychiatric Publishing Textbook of Psychiatry, Edited by R. E. Hales, S. C. Yudofsky, L. W. Roberts, Sixth Edition, Edra (2014). Manuale di Psichiatria, Editors: Sacchetti E., Mencacci C., Aguglia E., Albert U., Altamura C., Bogetto F., Clerici M., Colombo C., **Pallanti S.**, Santonastaso P., Smeraldi E., Zanalda E., Zuddas A.

#### Digital Publications

2009 - 2013 CD-ROM for the the Managing Anxiety in Practice (MAP) educational programme

#### Thesis

1. **Pallanti S.** (1983) Life events and Depression, Dissertation thesis for Medical Doctorate Degree and European Medical License, University of Florence, School of Medicine, Florence, Italy.
2. **Pallanti S.** (1987) Life events and Schizophrenia, Dissertation thesis for PhD in Psychiatry, University of Florence, School of Medicine, Florence, Italy.
3. **Pallanti S.** (1992) Contingent Negative Variation (CNV) in normal elderly population, Dissertation thesis for PhD in Neurophysiopathology, University of Florence, School of Medicine, Florence, Italy.

#### EDITORIAL SERVICE

##### Editorial Board Memberships

Since 2000 Eating and Weight Disorders  
 Since 2006 Journal of Gambling Studies  
 Since 2010 Austin Child & Adolescent Psychiatry  
 Since 2012 CNS Spectrums – International Journal of Neuropsychiatric Medicine  
 Since 2012 Frontiers in Psychiatry  
 Since 2012 Giornale Italiano di Psicopatologia  
 Since 2014 British Association for Psychopharmacology Journal  
 Since 2014 International Journal of Psychiatry in Clinical Practice  
 Since 2016 Journal of Addiction and Therapy  
 Since 2016 Journal of Psychiatry & Mental Disorders  
 Since 2016 SM Journal of Psychiatry & Mental Health  
 Since 2019 Real World Psychiatry and Psychopharmacology

### Editor/Editor in Chief

2000 & 2006 CNS Spectrums – International Journal of Neuropsychiatric Medicine: Guest Editor  
2008 - 2010 American Journal of Psychiatry Italian edition: Editor in Chief  
Since 2017 CNS Spectrums – International Journal of Neuropsychiatric Medicine: Field Editor  
2019 Archive of Behavioral Addiction: Editor in chief

### International Advisor

2008 – 2012 American Psychiatric Publishing

### Reviewer

Since 2000 American Journal of Psychiatry  
Since 2000 JAMA of Psychiatry  
Since 2000 Journal of Psychiatric Research  
Since 2002 Biological Psychiatry  
Since 2004 Journal of Clinical Psychiatry  
Since 2006 European Neuropsychopharmacology  
Since 2010 Lancet  
Since 2010 Progress in Neuro-Psychopharmacology & Biological Psychiatry  
Since 2010 Psychiatry Research

### GRANTS

#### Current Funding as Principal Investigator

2012 -2018 Phase IV “A non-interventional prospective cohort study of patients with persistent symptoms of schizophrenia to describe the course and burden of illness. Italian Society for Psychopathology 2012; Phase II “A phase 2, randomized, double-blind, placebo-controlled study to evaluate the effect of add-on AMG 747 on schizophrenia negative symptom” AMGEN, Clinical Trial NCT01568229

2017 – 2021 R21 Grant, The National Institute of Mental Health: "Modulating Inhibitory Control Networks in Gambling Disorder with Theta Burst Stimulation". MPI: Nikolas Makris; Role: Co-I. Clinical Trial NCT03669315

#### Research Funding Under Review

PRIN GRANT -Italian Ministry of Education for University and Research: "Repetitive Transcranial Magnetic Stimulation targeting inhibitory control networks in Anorexia Nervosa" PI: Pallanti

ERA-NET NEURON (Call for transnational research projects 2016 - 'European Research Projects on External Insults to the Nervous System') "Role of repetitive Transcranial Magnetic Stimulation (rTMS) in Protease-Activated Receptor 1 (PAR1)-mediated alterations

in synaptic plasticity for the treatment of traumatic brain injury sequels.” Plast4TBI, PI: Pallanti (for Italy)

### Past Research Funding as Principal Investigator

- 2005 RESEARCH FUND, research on “Transcranial Magnetic Stimulation in Resistant Depression”, Italian Ministry of Health
- 2007 PRIN GRANT, research on Panic Disorder, Italian Ministry of Education for University and Research
- 2009 Ondansetron Augmentation in Treatment Resistant Obsessive-Compulsive Disorder, A single-blind, prospective study. Transcept Pharmaceuticals Inc. (CA), USA
- 2009 GRANT for Collaboration agreement of Leland Stanford Junior University and University of Florence, Italian Ministry of Education for University and Research
- 2009 Efficacy of Agomelatine, A randomised double-blind, placebo-controlled, parallel groups, international study. SERVIER INTERNATIONAL, France
- 2010 International Multicenter Snapshot Study of OCD patients. INTERNATIONAL COLLEGE OF CLINICAL OCD (ICOCS)
- 2012 Phase II “A randomized, double-blind study comparing the efficacy and safety of tradozone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder” ANGELINI
- 2012 Lurasidone: A 12-week multicenter open label study in subjects with Schizophrenia. LATUDA 2011 Phase III “Double blind placebo-controlled trial of Armodafinil in the treatment of Bipolar Depression” TEVA, Clinical Trial NCT01072929

### PRESENTATIONS

#### International Meetings

- 2002 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*Attentional Dysfunction in OCD Spectrum*”
- 2003 Course Director, Chairman and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*OCD and ADHD: a translational approach*”
- 2004 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*Resistant OCD: Hoarding and attentional dysfunction*”
- 2004 Organizer, Course Director, Chairman, and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** “*Anxiety and Impulsivity*”
- 2004 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*OCD spectrum and comorbidities*”
- 2004 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*Neuromodulation for OCD: new targets*”
- 2004 Poster Award **European College of Neuropsychopharmacology (ECNP)** “*Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study*”

- 2005 Lecturer **Stand Alone Lecture Tour in Japan** on “*New Vision of Pharmacological Intervention for the Acute Psychotic Patient*” (Tokyo, Yamanashi, Iwate and Kobe)
- 2005 Invited speaker **European College of Neuropsychopharmacology (ECNP)** (Paris) “*Treatment-resistant Obsessive-Compulsive Disorder: a translational vision*”
- 2005 Invited Speaker at **World Psychiatric Association (WPA)** “*Improving remission in depression in Mediterranean countries*”
- 2005 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*Treatment of difficult OCD*”
- 2005 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*Accelerating response to treatment of OCD*”
- 2005 Organizer, Course Director, Chairman, and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** “*Compulsivity-impulsivity and Pathological Gambling*”
- 2006 Invited Speaker **European College of Neuropsychopharmacology (ECNP)** (Amsterdam) “*Gambling as compulsive disorder*”
- 2006 Invited Speaker at **World Psychiatric Association (WPA)** “*Anxiety Comorbidities and Role of Emotion in Endophenotype of Schizophrenia*”
- 2006 Invited Speaker (Florida) **American College of Neuropsychopharmacology** “*Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder*”
- 2006 Lecturer **Solvay Pharmaceuticals Middle East Symposium** (Beirut) “*Social anxiety disorder: Assessment and treatment with SSRI*”
- 2006 Invited Speaker **International Anxiety Disorders Conference** (Cape Town) “*Resistant social anxiety disorder: how to get response*”
- 2006 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*Pharmacological challenge in OCD*”
- 2006 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*OCD: Anxiety or addictive disorder?*”
- 2006 Organizer, Course Director, Chairman, and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** “*Treatment of psychiatric disorder in the Day Hospital*”
- 2007 Invited Speaker at **World Psychiatric Association (WPA)** “*Residual symptoms in depression*”
- 2007 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*Children with OCD: How to detect and treat*”
- 2007 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*Glutamate pathway in OCD*”
- 2007 Organizer, Course Director, Chairman, and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** “*Emotional endophenotype and schizophrenia*”; “*Resistant Depression: new treatment options*”
- 2007 Invited Speaker, **ECNP Targeted Expert Meetings (TEM)** Participant (Vienna) “*Behavioral and substance addictions: a new category*”
- 2007 Spokesman and Lecturer (Web Conference with Japan) **Eli Lilly Web Conference Marketing in Japan** “*Treatment of Acute Psychosis and Schizophrenia*”
- 2008 Chairman of Symposium, **ECNP TEM Meetings** Participant, (Barcelona) “*Dopamine and behavioral addictions*”

- 2008 Course Director, Chairman and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*Endophenotype of impulsive-obsessive spectrum?*”
- 2008 Chairman and Invited Speaker, **International Forum on Mood and Anxiety Disorders (IFMAD)** (Vienna) “*Is there an impulsive-obsessive spectrum?*”
- 2008 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*Social Anxiety in OCD disorders*”
- 2008 Organizer, Course Director, Chairman, and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** “*PANDAS: assessment and treatment*”
- 2008 Chairman and Speaker at Dinner Symposium on “Impulsive-Compulsive Spectrum Disorders: Diagnostic Issues”, **American Psychiatric Association (APA)** (Washington DC) “*Pharmacological treatments of pathological gambling*”
- 2008 Plenary Lecture **World Psychiatric Association (WPA)** “*Adherence to treatment*”
- 2009 Speaker at **American Psychiatric Association (APA)** “*Unilateral low frequency versus sequential bilateral rTMS: is simpler better for treatment of resistant depression?*”
- 2009 Lecturer **Stand Alone Lecture Tour in Japan** on “*New Vision of Pharmacological Intervention for the Acute Psychotic Patient*” (Tokyo, Aomori, Gumma, Tokushima, Fukuoka and Kobe) “*Acute schizophrenia*”
- 2009 Course Director, Chairman and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*PANDAS and PANS*”
- 2009 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*Depression, OCD and neuroinflammation*”
- 2009 Organizer, Course Director, Chairman and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** “*Farmaci oltre lo studio STAR*”, “*Neuroimaging of Pathological Gambling*”
- 2009 Chairman and Invited Speaker, TEM Meetings participant, Plenary Lecture **European College of Neuropsychopharmacology (ECNP)** (Istanbul) “*Pharmacological challenge in OCD and gambling disorder*”
- 2009 Invited Speaker and co-chair of Symposium **World Psychiatric Association (WPA)** (Florence) “*Behavioral addictions, impulsivity and OCD*”
- 2009 Lecturer **Solvay Pharmaceuticals Middle East Symposium** (Beirut) “*Treatment of depression with selective serotonin inhibitors*”
- 2009 Invited Speaker **International Anxiety Disorders Conference** (Amsterdam) “*OCD : beyond Anxiety disorders*”
- 2009 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich and Paris) **MAP – Managing Anxiety in Practice – Pfizer International** “*Management and treatment of GAD*”
- 2009 Invited Speaker **XV Update In Psychiatry** (Vienna) “*Range of obsessive-compulsive disorders*”
- 2009 Invited Speaker **International Anxiety Disorders Conference** (Amsterdam) “*OCD anxiety affective condition*”
- 2010 Chairman and invited speaker, TEM Meetings participant, Plenary Lecture (Amsterdam) **European College of Neuropsychopharmacology (ECNP)** “*Ondansetron augmentation in Treatment-Resistant OCD (TR-OCD): Relapse in Y-BOCS symptoms following discontinuation of ondansetron*”
- 2010 Course Director, Chairman and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*Approaches to Treatment Resistance in OC Spectrum*”

- 2010 Chairman and Invited Speaker, **International Forum on Mood and Anxiety Disorders (IFMAD)** (Vienna) *“Augmentation strategies in resistant OCD”*
- 2010 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich and Paris) **MAP – Managing Anxiety in Practice – Pfizer International** *“Comorbid Anxiety in Bipolar Disorder and Psychotic Disorders: Impact on Outcome”* *“Managing Anxiety in Practice. Generalised Anxiety Disorder: The Hidden Companion”*,
- 2010 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** *“PANDAS and PANS: is there an inflammation in OCD?”*
- 2010 Organizer, Course Director, Chairman and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** *“Trauma e Psicopatologia nella Vita Quotidiana”*, *“La Stimolazione Magnetica Transcranica nella depressione”*, *“Valutazione e trattamento della comorbidità per ansia nelle psicosi”*, *“Contributi della Stimolazione Magnetica Transcranica allo studio della consapevolezza: dove la Neuroscienza incontra la Filosofia”*
- 2010 Chairman of the TEM meetings and Invited speaker (Paris) **European College of Neuropsychopharmacology (ECNP)** *“Ondansetron augmentation in Treatment-Resistant OCD: Twelve Week, Single-blind, Prospective Study Data”*
- 2010 Lecturer **Solvay Pharmaceuticals Middle East Symposium** (Beirut (Lebanon), Amman (Jordan), Cairo, Alexandria, Ain Sokhna, (Egypt)) *“Somatic depression and SSRI”*
- 2010 Lecturer **Solvay Pharmaceuticals Middle East Symposium** (Zagreb) *“SSRI and Sigma receptors”*
- 2010 Invited Speaker **Servier CL2-20098-072 Study Investigators Meeting** (Amsterdam) *“Efficacy of agomelatine in Obsessive-Compulsive Disorder.”*
- 2010 Invited Speaker **Eli Lilly NERI European Consultant Advisory Board Meeting** (Madrid) *“Subjective Experience and Basic Symptoms in Schizophrenic Patients”*
- 2011 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich and Paris) **MAP – Managing Anxiety in Practice – Pfizer International** *“Anxiety in women: special considerations”* *Neurotrophic Factors in GAD: A Closer Look at Brain-derived Neurotrophic Factor and Artemin*
- 2011 Invited Speaker, Thematic Conference (Istanbul) **World Psychiatric Association (WPA)** *“Gambling ADHD and mood stabilizers”*
- 2011 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** *“Mood stabilizers in impulse control disorders”*
- 2011 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** *“Update on Agomelatin Preclinical and Clinical Data”*
- 2011 Organizer, Course Director, Chairman, and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** *“Recovery from OCD: a possible definition?”*; *“TMS in Depression and other clinical conditions”*
- 2011 Chairman of the TEM meetings and Invited speaker (Paris) **European College of Neuropsychopharmacology (ECNP)** *“Anxiety in the life span”* *“Disgust, passive-avoidance and treatment response in OCD”*
- 2011 Invited Speaker (New York) **Icare4Autism** *“Autism: Social Anxiety and executive dysfunction in adults”*
- 2011 Invited Speaker (Milan) **INNOPSY - International Forum Innovation in Psychiatry** *“Major Psychoses: Old concepts or new diagnostic clinical and therapeutic challenges”*

- 2011 Invited Speaker (Florence) **3<sup>rd</sup> International Cardio Event – University of Florence** “*Emotional distress and Cardiovascular diseases: Non-Pharmacological interventions*”
- 2011 Invited Speaker (Thessaloniki) **2nd Panhellenic Inter-scientific Congress of the Hellenic Association for the Study of Internet Addiction Disorder** “*Internet Addiction Disorder*”
- 2011 Invited Speaker **European Congress of Psychiatry (EPA)** (Vienna) “*Generalized Anxiety Disorder*”, “*Low frequency rTMS in elderly*”
- 2012 Course Director and Invited Speaker (London) **MAP – Managing Anxiety in Practice – Pfizer International** “*The GAD patient in focus*”
- 2012 Chairman and Invited Speaker (Jerusalem) **Icare4Autism** “*Bio-Medical Research and Practice*”
- 2012 Course Director, Chairman and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*Treatment of anxiety in bipolar disorder*”
- 2012 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*Treatment of OCD in bipolar disorder*”
- 2012 Organizer, Course Director, Chairman and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** “*Application of rTMS in the OCD spectrum*”; “*PANDAS and PANDAS like in Psychiatry*”
- 2012 Chairman of the TEM meetings and Invited speaker (Vienna); **European College of Neuropsychopharmacology (ECNP)** (Vienna) Chair, Brain Storming Session “*Time for Immuno Psychiatry?*”
- 2012 Scientific Advisers Chair **IFMAD International Forum on Mood and Anxiety Disorders** (Barcellona) “*Development in the treatments of Anxiety disorders*”, “*Is Hoarding a separate disorder?*”
- 2013 Course Director and Invited Speaker (Berlin) **MAP – Managing Anxiety in Practice – Pfizer International** “*Managing anxiety in practice: GAD now and beyond*”
- 2013 Member of the Board of Directors and Invited Speaker **Clinical TMS Society Meeting**: “*TMS in mixed bipolar episode*”
- 2013 Member of the Editorial Board and Invited Speaker **CNS Spectrum Meeting** “*The Emotional Endophenotype in Schizophrenia*”
- 2013 Invited Speaker (Brescia) **Brixia International Meeting – University of Brescia, Italy** “*Pathological gambling: new diagnostic boundaries and treatment options*”
- 2013 Chairman of the TEM meetings and Invited speaker **European College of Neuropsychopharmacology (ECNP)**(Barcellona) “*The role of anxiety in impulsive and compulsive disorders*”
- 2013 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*ADHD in bipolar disorder: Assessment and treatment*”
- 2013 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*TMS for OCD: where are the targets?*”
- 2013 Organizer, Course Director, Chairman, and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** “*ADHD adulto e disturbo bipolare*”
- 2013 Speaker, **Stanford University**, Florence, Italy. “*The Trapped Brain (Gambling, Internet addiction and other pathologies: how to recognize and prevent them*”
- 2013 Invited Speaker (Kuala Lumpur) **International Society of Addiction Medicine (ISAM) Conference** “*Internet Addiction: NO Substance Addiction?*”

- 2013 Chairman, Co-Chairman, Invited Speaker (Milano) **World Congress on ADHD** Chair: *"How to do best medication in adult ADHD?"*; Co-Chair: *"Update on treatment of ADHD across the lifespan"*
- 2014 Member of the Editorial Board and Invited Speaker **CNS Spectrum Meeting** *"rTMS as an add-on therapeutic tool in treatment refractory obsessive-compulsive disorder"*
- 2014 Member of the Board of Directors and Invited Speaker **Clinical TMS Society Meeting** *"Low frequency bilateral rTMS in resistant OCD subjects: does the effect last?"*
- 2014 Invited Speaker (Madrid) **World Psychiatric Association (WPA)** *"Repetitive behavior disorders as a target for focal treatment"*
- 2014 Chairman and Invited Speaker (Online meeting) **Eli Lilly ADHD in Adult: Raise the Awareness of a Disease Still Unknown and Not Recognized** *"TMS for ASD and OCD"*
- 2014 Chairman of the TEM meetings and Invited speaker **European College of Neuropsychopharmacology (ECNP)** (Berlin) *"Adult separation anxiety disorder: boundaries causes and potential treatments"*; *"Is a paradigm shift in Psychiatry long overdue?"*
- 2014 Course Director, Chairman and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** *"Obsession and compulsion: an R-Do.C approach"*
- 2014 Chairman and Invited Speaker, **International Forum on Mood and Anxiety Disorders (IFMAD)** (Vienna) *"Pharmacologic treatment of Obsessive-compulsive comorbidity"*; *"How to treat anxiety with comorbidity"*
- 2014 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** *"Neuromodulation: deep TMS and rTMS"*
- 2014 Organizer, Course Director, Chairman and Invited Speaker (Florence) **Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS** *"Curare le comorbidità"*; *"Neuromodulazione per i disturbi resistenti"*
- 2015 Invited Speaker (Brescia) **Brixia International Meeting – University of Brescia, Italy** *"Pluses and minuses of DSM-5 in depression and Anxiety disorders"*; *"Neurobiology of addictive behaviors"*
- 2015 Member of the Editorial Board and Invited Speaker **CNS Spectrum Meeting** *"The clinician as a translational scientist"*
- 2015 Member of the Board of Directors and Invited Speaker **Clinical TMS Society Meeting** *"OCD with theta burst stimulation (TBS) of the pre-supplementary motor area (pre-SMA)."*
- 2015 Scientific Advisory Board and Chairman of the TEM meeting and Invited speaker **European College of Neuropsychopharmacology (ECNP)** (Amsterdam) *"Separation anxiety in adults"*
- 2015 Invited Speaker (Milan) **EXPO 2015 Symposium "Il Futuro della Salute Mentale" (Future of the Mental Health)** *"The Obsessive-Compulsive Patient"*
- 2015 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** *"Separation anxiety in ADHD"*
- 2015 Chairman and Invited Speaker, **International Forum on Mood and Anxiety Disorders (IFMAD)** (Prague) *"Pluses and minuses of DSM-5 in depression and anxiety disorders"*
- 2015 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** *"Multicenter rTMS trial"*



- 2016 Invited Speaker (Brescia) **Brixia International Meeting – University of Brescia, Italy** “*Neuromodulation of compulsive disorder: Experience and perspectives*”; “*Behavioral addiction: decision making and executive function disorder*”
- 2016 Member of the Editorial Board and Invited Speaker **CNS Spectrum Meeting** “*Executive functions and OCD*”
- 2016 Member of the Board of Directors and Invited Speaker **Clinical TMS Society Meeting** “*TMS for autism spectrum disorders*”
- 2016 Scientific Advisory Board, Chairman of the ECNP Targeted Expert Meetings (TEM) meeting and Invited speaker **European College of Neuropsychopharmacology (ECNP)**(Vienna) “*Future perspectives for treatment of anxiety disorders*”
- 2016 Chair of Symposium on “New neural treatment targets in compulsive disorders” (Atlanta, GA) **American Psychiatric Association (APA)** “*Repetitive behavior disorders as a target for focal treatment: TMS for ASD and OCD*”
- 2016 Expert in Psychiatry, Chair and Invited Speaker (Bangkok) **4<sup>th</sup> ACNS – Asian Clinical Neurosciences Summit Speaker** “*What is an integrated approach, and how does it help patients to achieve functional recovery?* Expert Session: “*Treatment of bipolar disorder patient with comorbid metabolic disorder*”; Speaker “*Targeting neuroinflammation in psychiatry: a prelude to optimal treatment?*”; Speaker: “*Reframing women’s mental health: what are we missing?*”
- 2016 Course Director, Chairman and Invited Speaker (Florence) European Certificate, **International Master in Affective Neuroscience** “*Fear, Obsession and Trauma*”
- 2016 Chairman and Invited Speaker, **International Forum on Mood and Anxiety Disorders (IFMAD)** (Rome) “*How should we treat resistant OCD?*”
- 2016 Member of the Board of Directors and Invited Speaker **International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS)** “*Pre-SMA target for TMS in OCD*”
- 2016 Stand Alone Web Cast Lecturer (Online World-wide) **Pfizer CNS World-wide Web Cast Series** “*Neuro-inflammation and Mental Disorders*”
- 2016 Executive Committee Meeting (Madrid) **European College of Neuropharmacology (ECNP)** “*Future perspectives for the treatment of anxiety disorders*”
- 2017 **SOPSI Società Italiana di Psicopatologia annual meeting**, Speaker, “*La Neuromodulazione nella depressione maggiore*”
- 2017 Executive Committee Meeting (Nice) **European College of Neuropharmacology (ECNP)**
- 2017 **25<sup>th</sup> European Congress of Psychiatry (EPA)**, Firenze  
Speaker “*Anxiety disorders and somatiform disorders: depression, obsessive-compulsive disorder and personality disorders*”  
Symposium “*Impulsivity, Compulsivity and Behavioral Addiction*”  
Symposium “*New neural treatment targets in compulsive disorders*”  
E-Poster Walk
- 2018 I trattamenti farmacologici nel processo terapeutico-riabilitativo del consumatore di sostanze, Firenze  
Speaker “*Le radici neurobiologiche dei trattamenti non farmacologici in ambito integrato*”
- 2018 **International Conference on Transcranial Magnetic Stimulation and addiction treatments**, Torino, Italy, 20 April 2018. Speaker “*Neuromodulation of impulsivity and compulsivity: targeting inhibitory control networks across impulsive-compulsive disorders?*”
- 2018 **Weekend seminar in india**, Bangalore, 25 – 27 May 2018. Speaker and Discussant, “*Treating Resistant OCD*”

- 2018 **European College of Neuropharmacology (ECNP)**, Barcelona, Spain, 6 – 9 October 2018.  
Chair “Transcranial Magnetic Stimulation (TMS): From benchmark to bedside”  
Speaker “Highlights in OCD and related disorders”  
Executive Committee Meeting
- 2018 **Italian Society of Psychiatry Meeting**, Torino, Italy, 16 October 2018.  
Presentation: Cariprazine: Clinical usefulness and therapeutic experience in the real world
- 2018 Executive Committee Meeting (Toledo) **European College of Neuropharmacology (ECNP)**, 16 – 18 December 2018
- 2019 **XXIII SOPSI Società Italiana di Psicopatologia annual meeting**, Speaker, Cariprazine and personalized care, ADHD throughout life, ADHD: Neurological signs and subjective experience, 20 – 23 February 2019
- 2019 **Sage Therapeutics, Inc. European Advisory Board** “the potential role of the GABA pathway in the future management of depressive episodes” 5 April 2019
- 2019 **Octapharma PANS Advisory Board Meeting**, Phoenix 27 April 2019
- 2019 **MilanoPsichiatria**, Speaker, 1. Evolution of pharmacotherapy in schizophrenic spectrum disorders: from control to treatment, 2. Behavioral Addictions: Beyond Gambling, 3. Personalized TMS for depression. Discussant: Where a gambling policy can go that leaves internet gaming and illegal gambling at the margins? 13 – 16 May, 2019
- 2019 Società Italiana di Psichiatria, Speaker, Cariprazina: Valore Terapeutico “Making Sense” di un nuovo Strumento di Cura, Torino, 21 May 2019
- 2019 **IFMAD Internarnational Forum on Mood and Anxiety Disorders**, Speaker, Personalized rTMS in Depression, 4 - 6 July 2019, Wien
- 2019 **Psychiatry Academy of the Harvard University and the Massachusetts General Hospital**, Faculty, Session 1. Bipolar Depression and Mixed Features” Session 2. “Updates on TMS in Depression”
- 2019 32<sup>nd</sup> ECNP Congress, Copenhagen, Task Force network Meeting, Industry Network Meeting, TWG meeting, 1st EC Meeting, Satellite Symposia – Speaker “Patient functioning in schizophrenia: can we change the burden?” 7 – 10 September 2019
- 2019 Comprehensive Psychiatry Editorial Board Meeting Elsevier, Copenhagen 10 September 2019
- 2019 12° Congresso Società Italiana Psichiatria Biologica, Napoli, 2 – 4 October 2019  
Speaker “Utilizzo della TMS nei Disturbi Psichiatrici”
- 2019 Emozioni, Conoscerle, Indurle Gestirle Firenze, 9 November 2019  
Speaker “Disgusto, disprezzo ed altre figure del dis-amore”
- 2019 Albert Einstein College of Medicine lecture “TMS in the impulsive-compulsive spectrum” 17 December 2019
- 2020 ECNP Task Force Meeting, Leiden, 10 February 2020
- 2020 Società Italiana di Psicopatologia, Speaker “L’evoluzione della farmacoterapia nella schizofrenia: Cariprazina e il Perché di un cambiamento”, Roma, 20 February 2020
- 2020 European Commission consensus initiative on depression and its treatment (London), 22 May 2020
- 2020 First Master Training Class in Neuromodulation, Organizer and Speaker, “Clinical findings of TMS in OCD spectrum”, Online event, 5-6 June 2020
- 2020 Advisory Board on Trazodone, Speaker, Online event, 23 July, 4 August 2020
- 2020 VI Convegno di Epigenetica, Urbino. Speaker “Il cervello soffre: dalla vita alla clinica” 3-4 October, 2020. Istituto di Medicina Naturale
- 2020 Corso Microbiota: aspetti fisiopatologici, clinici e terapeutici, Speaker, 30 October 2020. Università di Firenze.

- 2020 SCOPUS International Webinar. Speaker, COVID pandemic and its impact on Mental Health. 27 August 2020, New Delhi, India
- 2020 2nd Forum of Advanced Training in Psychiatry. 3-4 December 2020. Brescia, Italy  
Speaker, Prevenzione, interventi precodi e nuove opportunità di trattamento nella schizofrenia e nei disturbi dell'umore.
- 2021 XXII Congresso Nazionale SINPF, Società Italiana di NeuroPsicoFarmacologia.  
Speaker, Disturbi dello spettro schizofrenico; dal controllo alla Recovery attraverso la cura: esperienze con cariprazina. 28 January 2021.
- 2021 Web Forum Disturbi cognitivi e depressivi dell'anziano. Speaker, attualità ed innovazioni terapeutiche. 2 February 2021. Accademia di terapia naturale
- 2021 Simposium Psicofarmaco terapia spettro schizofrenico. Speaker, Dal recupero clinico oggettivo e funzionale al recupero personale. 28 February 2021. Accademia delle Terapie Naturali.
- 2021 3rd International Psychopharmacology course, Depression & Schizophrenia. International Perspectives on Global Disorders. Speaker, Bipolar Depression: How do we treat it? 14 May 2021. Harvard University and Massachusetts General Hospital Psychiatry Academy.

### Grand Rounds

- 2012 University of Sydney, Brain and Mind Institute, Sydney, Australia "*Social Anxiety in Autism Spectrum Disorders: a new target for new treatments?*"
- 2013 Albert Einstein College of Medicine of Yeshiva University, New York, USA "*Psychoses and Anxiety*"
- 2016 Center for Neuropsychopharmacology, Centre for Restorative Neuroscience, Division of Brain Sciences, Faculty of Medicine, Imperial College, London, UK "*Investigating and Treating Compulsivity with neuromodulation*"

*Development of an assessment tool for pathological gambling* PG-YBOCS (Pathological Gambling Yale-Brown Obsessive-Compulsive Scale)

### *Paid Consultancy Agreements*

- 2000 - 2001 Solvay International (Fluvoxamine)
- 2001 - 2013 Pfizer (Pregabalin SR)
- 2005 Ely Lilly
- 2006 - 2013 Transcept Pharmaceutical (Ondansetron)
- 2007 Ely Lilly
- 2007 - 2008 GSK (Bupropion SR)
- 2007 - 2008 Jazz Pharmaceutical (Fluvoxamine)
- 2007 - 2010 An International Tobacco Company (Nicotin Dipendence Litigation)
- 2008 Brainsway (Neuromodulation technology)
- 2009 Astrazeneca
- Intramed
- Ely Lilly
- Innova Pharma
- 2010 Intramed
- Mind Education and Reserch in Neuroscience and Medicine
- Abbot Laboratories Egypt

	Ely Lilly
	Solvay Group
	Lundbeck
2011	Grunenthal GmbH
	Servier Group
	Innova Pharma
	Lundbeck
2012	Chadbourne & Parke LLP, London, UK
	Innova Pharma
	Alkermes Pharmaceuticals
	Lundbeck
	ALKS-5461 MDD Advisory Board, Alkermes Plc
	ProPhase, LLC
	Angelini
	Servier Group
	Biotest AG
	Sunovion Pharmaceuticals
	Otsuka Pharmaceutical
2013	Chiltern International
	Innova Pharma
	Agence Nationale de la Recherche, ANR France
	Pfizer Limited
	Stanford University, Florence, Italy
	Innova Pharma
	Spectrum Neuroscience and Treatment Institute
2014	Ely Lilly
	Innova Pharma
	Agence Nationale de la Recherche, ANR France
2015	Ely Lilly
	Innova Pharma
2016	L.E.K. Consulting
	Innova Pharma
	Recordati
2017	Recordati
	Innova Pharma
2018	Sage Therapeutics Inc
	Recordati
	Swiss National Science Foundation (SNSF)
	Innova Pharma
2019	Octapharma
	Neurocrine Biosciences
	Recordati
	Sage Therapeutics
	L.E.K. Consulting
	Swiss National Science Foundation (SNSF)
	Pfizer
	Centro di Terapia Strategica srl
	Innova Pharma
2020	Recordati
	The Forensic Panel
	L.E.K. Consulting
	Biohaven Pharmaceuticals, inc

EMBS Group spółka z ograniczoną odpowiedzialnością spółka komandytowa  
 Angelini Pharma  
 GEDEON RICHTER Plc  
 Association of Analytical Child and Adolescent Psychotherapists in Germany  
 (Vereinigung Analytischer Kinder- u. Jugendlichen-Psychotherapeuten in  
 Deutschland e. V., VAKJP)  
 Swiss National Science Foundation (SNSF)  
 Innova Pharma  
 2021 Recordati  
 Biohaven Pharmaceuticals, inc  
 Angelini Pharma  
 GW Research Limited  
 Innova Pharma  
 Swiss National Science Foundation (SNSF) for Spark funding instrument  
 Lundbeck  
 Otsuka Pharmaceutical  
 Aboca  
 Biogen  
 Menarini

#### LITIGATION HISTORY: Won all cases reviewed and worked

##### Plaintiff work

2013: Military Jurisdiction: Compagnia Carabinieri (Italian Armed Military Police Force) against a criminal previously sentenced not guilty

2018: Damage against an Insurance company

##### Defense Trials

2006-2007: Class action performed by a cohort of workers who claimed to be victims against Boeringer UK

2012-2013: Noise pollution action performed by a cohort of people who claimed to be victims against Phillip Morris / Smurfit Kappa

2012 A lottery betting shop owner (a pathological gambler) sued by Italian Ministry of Treasury

2016: A medical doctor sued by his patient for sexual harassment

2011-2020: 9 cases (family, work and accidents)

#### COMMUNITY SERVICE

2000 Technical and Scientific Medical Consultant for the Italian Ministry of University and Scientific Research and Technology

2000 - Present "Forteto" Litigation case Consultant

2000 – Present      Servants of the Holy Paraclete Consultant

2012 - Present      Technical Consultant for the Avvocatura dello Stato (Italian Republic  
State Advocacy)